Definitive Healthcare (DH) 10-Q 7 Nov 24 2024 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2024	Nov. 04, 2024
Document Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Entity Registrant Name	Definitive Healthcare Corp.
Entity Central Index Key	0001861795
Entity Tax Identification Number	86-3988281
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity File Number	001-40815
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	492 Old Connecticut Path, Suite 401
Entity Address, City or Town	Framingham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01701
City Area Code	508
Local Phone Number	720-4224
Trading Symbol	DH
Title of 12(b) Security	Class A Common Stock, $0.001 par value
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Entity Common Stock Shares Outstanding		115,522,829
Document Transition Report	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 137,609	$ 130,976
Short-term investments	167,779	177,092
Accounts receivable, net	35,754	59,249
Prepaid expenses and other current assets	14,049	13,120
Deferred contract costs	13,486	13,490
Total current assets	368,677	393,927
Property and equipment, net	3,704	4,471
Operating lease right-of-use assets, net	8,274	9,594
Other assets	1,989	2,388
Deferred contract costs	14,136	17,320
Intangible assets, net	294,530	323,121
Goodwill	490,343	1,075,080
Total assets	1,181,653	1,825,901
Current liabilities:
Accounts payable	9,961	5,787
Accrued expenses and other liabilities	35,751	51,529
Deferred revenue	86,219	97,377
Term loan	13,750	13,750
Operating lease liabilities	2,495	2,239
Total current liabilities	148,176	170,682
Long term liabilities:
Deferred revenue	21	9
Term loan	232,668	242,567
Operating lease liabilities	8,277	9,372
Tax receivable agreements liability	59,013	127,000
Deferred tax liabilities	30,767	67,163
Other liabilities	7,171	9,934
Total liabilities	486,093	626,727
Equity:
Additional paid-in capital	1,087,555	1,086,581
Accumulated other comprehensive income	344	2,109
Accumulated deficit	(581,499)	(227,450)
Noncontrolling interests	189,045	337,817
Total equity	695,560	1,199,174
Total liabilities and equity	1,181,653	1,825,901
Common Class A
Equity:
Common stock, value	115	117
Common Class B
Equity:
Common stock, value	$ 0	$ 0

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Common Class A
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	600,000,000	600,000,000
Common stock, shares issued	115,443,795	116,562,252
Common stock, shares outstanding	115,443,795	116,562,252
Common Class B
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	65,000,000	65,000,000
Common stock, shares issued	39,460,224	39,762,700
Common stock, shares outstanding	39,393,407	39,168,047

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Revenue	$ 62,697	$ 65,325	$ 189,914	$ 185,483
Cost of revenue:
Cost of revenue exclusive of amortization	10,077	8,663	29,717	25,293
Amortization	3,589	3,232	10,330	9,676
Gross profit	49,031	53,430	149,867	150,514
Operating expenses:
Sales and marketing	20,130	22,804	63,435	70,929
Product development	7,282	10,759	27,536	30,872
General and administrative	11,354	14,545	40,764	42,294
Depreciation and amortization	9,474	9,795	28,205	29,073
Transaction, integration and restructuring expenses	(1,995)	3,505	9,390	9,666
Goodwill impairment	228,153	287,400	591,794	287,400
Total operating expenses	274,398	348,808	761,124	470,234
Loss from operations	(225,367)	(295,378)	(611,257)	(319,720)
Other income (expense), net:
Interest income	3,742	3,464	11,386	9,870
Interest expense	(3,749)	(3,897)	(11,328)	(11,304)
Gain on remeasurement of tax receivable agreement liability	24,183	29,675	68,151	24,977
Other (expense) income, net	(357)	(86)	(85)	184
Total other income , net	23,819	29,156	68,124	23,727
Net loss before income taxes	(201,548)	(266,222)	(543,133)	(295,993)
Benefit from income taxes	13,724	17,534	36,404	19,728
Net loss	(187,824)	(248,688)	(506,729)	(276,265)
Less: Net loss attributable to noncontrolling interests	(56,928)	(77,162)	(152,680)	(84,110)
Net loss attributable to Definitive Healthcare Corp.	$ (130,896)	$ (171,526)	$ (354,049)	$ (192,155)
Net loss per share of Class A common stock:
Basic	$ (1.12)	$ (1.5)	$ (3.02)	$ (1.72)
Diluted	$ (1.12)	$ (1.5)	$ (3.02)	$ (1.72)
Weighted average Class A Common Stock outstanding:
Basic	116,382,021	114,527,514	117,185,701	111,533,166
Diluted	116,382,021	114,527,514	117,185,701	111,533,166

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]
Net loss	$ (187,824)	$ (248,688)	$ (506,729)	$ (276,265)
Other comprehensive income (loss):
Foreign currency translation adjustments	212	(30)	52	(134)
Unrealized gain (loss) on available-for-sale securities	286	205	111	(59)
Unrealized loss on interest rate hedging instruments	(1,459)	(442)	(2,508)	(686)
Comprehensive loss	(188,785)	(248,955)	(509,074)	(277,144)
Less: Comprehensive loss attributable to noncontrolling interests	(57,176)	(77,228)	(153,260)	(84,372)
Comprehensive loss attributable to Definitive Healthcare Corp.	$ (131,609)	$ (171,727)	$ (355,814)	$ (192,772)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TOTAL EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Class A Units	Class B Units	Additional Paid In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Noncontrolling Interest
Beginning Balance at Dec. 31, 2022	$ 1,481,945	$ 105		$ 970,207	$ (25,062)	$ 3,668	$ 533,027
Beginning Balance (in shares) at Dec. 31, 2022		105,138,273	50,433,101
Net loss	(15,972)
Net Income (Loss)					(12,063)		(3,909)
Other comprehensive income (loss)	(1,247)					(875)	(372)
Vested incentive units				(505)			505
Issuance of Class A Common Stock upon vesting of RSUs				828			(828)
Issuance of Class A Common Stock upon vesting of RSUs, shares		380,676
Shares withheld related to net share settlement	(1,530)			(1,530)
Shares withheld related to net share settlement (in shares)		(127,829)
Effect of LLC unit exchanges	(10,466)	$ 5		41,881			(52,352)
Effect of LLC unit exchanges, shares		4,771,545	(4,771,545)
Forfeited unvested incentive units			(34,623)
Equity-based compensation	11,128			7,811			3,317
Ending Balance at Mar. 31, 2023	1,463,858	$ 110		1,018,692	(37,125)	2,793	479,388
Ending Balance (in shares) at Mar. 31, 2023		110,162,665	45,626,933
Beginning Balance at Dec. 31, 2022	1,481,945	$ 105		970,207	(25,062)	3,668	533,027
Beginning Balance (in shares) at Dec. 31, 2022		105,138,273	50,433,101
Net loss	(276,265)
Net Income (Loss)	(192,155)
Ending Balance at Sep. 30, 2023	1,203,450	$ 116		1,077,332	(217,217)	3,051	340,168
Ending Balance (in shares) at Sep. 30, 2023		116,281,962	39,781,946
Beginning Balance at Mar. 31, 2023	1,463,858	$ 110		1,018,692	(37,125)	2,793	479,388
Beginning Balance (in shares) at Mar. 31, 2023		110,162,665	45,626,933
Net loss	(11,605)
Net Income (Loss)					(8,566)		(3,039)
Other comprehensive income (loss)	635					459	176
Vested incentive units				(390)			390
Issuance of Class A Common Stock upon vesting of RSUs				620			(620)
Issuance of Class A Common Stock upon vesting of RSUs, shares		309,694
Shares withheld related to net share settlement	(1,085)			(1,085)
Shares withheld related to net share settlement (in shares)		(105,249)
Effect of LLC unit exchanges	(5,880)	$ 3		23,934			(29,817)
Effect of LLC unit exchanges, shares		2,718,054	(2,718,054)
Forfeited unvested incentive units			(47,267)
Equity-based compensation	12,363			8,943			3,420
Distributions to noncontrolling interests	(2,827)						(2,827)
Ending Balance at Jun. 30, 2023	1,455,459	$ 113		1,050,714	(45,691)	3,252	447,071
Ending Balance (in shares) at Jun. 30, 2023		113,085,164	42,861,612
Net loss	(248,688)
Net Income (Loss)	(171,526)				(171,526)		(77,162)
Other comprehensive income (loss)	(267)					(201)	(66)
Vested incentive units				(5,086)			5,086
Issuance of Class A Common Stock upon vesting of RSUs				391			(391)
Issuance of Class A Common Stock upon vesting of RSUs, shares		214,549
Shares withheld related to net share settlement	(782)			(782)
Shares withheld related to net share settlement (in shares)		(75,217)
Effect of LLC unit exchanges	(6,400)	$ 3		23,231			(29,634)
Effect of LLC unit exchanges, shares		3,057,466	(3,057,466)
Forfeited unvested incentive units			(22,200)
Equity-based compensation	11,994			8,864			3,130
Distributions to noncontrolling interests	(7,866)						(7,866)
Ending Balance at Sep. 30, 2023	1,203,450	$ 116		1,077,332	(217,217)	3,051	340,168
Ending Balance (in shares) at Sep. 30, 2023		116,281,962	39,781,946
Beginning Balance at Dec. 31, 2023	1,199,174	$ 117		1,086,581	(227,450)	2,109	337,817
Beginning Balance (in shares) at Dec. 31, 2023		116,562,252	39,762,700
Net loss	(12,718)
Net Income (Loss)					(9,518)		(3,200)
Other comprehensive income (loss)	(585)					(451)	(134)
Vested incentive units				(784)			784
Issuance of Class A Common Stock upon vesting of RSUs		$ 2		2,532			(2,534)
Issuance of Class A Common Stock upon vesting of RSUs, shares		1,822,506
Shares withheld related to net share settlement	(5,806)	$ (1)		(5,805)
Shares withheld related to net share settlement (in shares)		(646,041)
Effect of changes in LLC ownership, including LLC unit exchanges	(616)			1,276			(1,892)
Effect of Changes in L L C Ownership Including L L C Unit Exchanges Shares		51,308	(51,308)
Forfeited unvested incentive units			(47,388)
Equity-based compensation	15,582			11,682			3,900
Ending Balance at Mar. 31, 2024	1,195,031	$ 118		1,095,482	(236,968)	1,658	334,741
Ending Balance (in shares) at Mar. 31, 2024		117,790,025	39,664,004
Beginning Balance at Dec. 31, 2023	1,199,174	$ 117		1,086,581	(227,450)	2,109	337,817
Beginning Balance (in shares) at Dec. 31, 2023		116,562,252	39,762,700
Net loss	(506,729)
Net Income (Loss)	(354,049)
Ending Balance at Sep. 30, 2024	695,560	$ 115		1,087,555	(581,499)	344	189,045
Ending Balance (in shares) at Sep. 30, 2024		115,443,795	39,460,224
Beginning Balance at Mar. 31, 2024	1,195,031	$ 118		1,095,482	(236,968)	1,658	334,741
Beginning Balance (in shares) at Mar. 31, 2024		117,790,025	39,664,004
Net loss	(306,187)
Net Income (Loss)					(213,635)		(92,552)
Other comprehensive income (loss)	(799)					(601)	(198)
Vested incentive units				(91)			91
Issuance of Class A Common Stock upon vesting of RSUs				742			(742)
Issuance of Class A Common Stock upon vesting of RSUs, shares		513,252
Shares withheld related to net share settlement	(969)			(969)
Shares withheld related to net share settlement (in shares)		(161,854)
Repurchases of Class A Common Stock, shares		(1,258,565)
Repurchases of Class A Common Stock	(7,003)	$ (1)		(9,667)			2,665
Effect of changes in LLC ownership, including LLC unit exchanges	86			2,083			(1,997)
Effect of Changes in L L C Ownership Including L L C Unit Exchanges Shares		170,481	(170,481)
Forfeited unvested incentive units			(4,277)
Equity-based compensation	8,842			6,637			2,205
Distributions to noncontrolling interests	(2,713)						(2,713)
Ending Balance at Jun. 30, 2024	886,288	$ 117		1,094,217	(450,603)	1,057	241,500
Ending Balance (in shares) at Jun. 30, 2024		117,053,339	39,489,246
Net loss	(187,824)
Net Income (Loss)	(130,896)				(130,896)		(56,928)
Other comprehensive income (loss)	(961)					(713)	(248)
Vested incentive units				(1,581)			1,581
Issuance of Class A Common Stock upon vesting of RSUs				390			(390)
Issuance of Class A Common Stock upon vesting of RSUs, shares		359,130
Shares withheld related to net share settlement	(495)			(495)
Shares withheld related to net share settlement (in shares)		(110,159)
Repurchases of Class A Common Stock, shares		(1,885,951)
Repurchases of Class A Common Stock	(8,034)	$ (2)		(10,985)			2,953
Effect of changes in LLC ownership, including LLC unit exchanges	388			1,297			(909)
Effect of Changes in L L C Ownership Including L L C Unit Exchanges Shares		27,436	(27,436)
Forfeited unvested incentive units			(1,586)
Equity-based compensation	6,296			4,712			1,584
Distributions to noncontrolling interests	(98)						(98)
Ending Balance at Sep. 30, 2024	$ 695,560	$ 115		$ 1,087,555	$ (581,499)	$ 344	$ 189,045
Ending Balance (in shares) at Sep. 30, 2024		115,443,795	39,460,224

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Cash flows provided by (used in) operating activities:
Net loss	$ (187,824)	$ (12,718)	$ (248,688)	$ (15,972)	$ (506,729)	$ (276,265)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization					1,719	1,391
Amortization of intangible assets					36,816	37,358
Amortization of deferred contract costs					11,463	9,475
Equity-based compensation					30,720	35,485
Amortization of debt issuance costs					527	527
Provision for doubtful accounts receivable					947	820
Non-cash impairment charges related to office leases					1,047	155
Goodwill impairment charges	228,153		287,400		591,794	287,400	$ 287,400
Tax receivable agreement remeasurement					(68,151)	(24,977)
Changes in fair value of contingent consideration					(3,240)	0
Deferred income taxes					(36,609)	(19,728)
Changes in operating assets and liabilities:
Accounts receivable					23,148	19,370
Prepaid expenses and other assets					(7,205)	(5,808)
Deferred contract costs					(8,275)	(13,020)
Contingent consideration					(602)	0
Accounts payable, accrued expenses and other liabilities					(5,173)	(1,589)
Deferred revenue					(12,136)	(14,113)
Net cash provided by operating activities					50,061	36,481
Cash flows (used in) provided by investing activities:
Purchases of property, equipment and other assets					(1,443)	(2,383)
Purchases of short-term investments					(192,670)	(213,613)
Maturities of short-term investments					207,504	174,830
Cash paid for acquisitions, net of cash acquired					(13,530)	(45,023)
Net cash used in investing activities					(139)	(86,189)
Cash flows used in financing activities:
Repayments of term loans					(10,313)	(5,156)
Taxes paid related to net share settlement of equity awards					(7,270)	(3,397)
Repurchases of Class A Common Stock					(15,037)	0
Payments of contingent consideration					(1,000)	0
Payments under tax receivable agreement					(6,950)	(246)
Payments of equity offering issuance costs					0	(30)
Member distributions					(2,811)	(10,693)
Net cash used in financing activities					(43,381)	(19,522)
Net decrease in cash and cash equivalents					6,541	(69,230)
Effect of exchange rate changes on cash and cash equivalents					92	(244)
Cash and cash equivalents, beginning of period		$ 130,976		$ 146,934	130,976	146,934	146,934
Cash and cash equivalents, end of period	$ 137,609		$ 77,460		137,609	77,460	$ 130,976
Supplemental cash flow disclosures:
Interest					10,886	10,772
Income taxes					0	136
Acquisitions:
Net assets acquired, net of cash acquired					13,675	52,659
Working capital adjustment receivable					(145)	164
Contingent consideration					0	(7,800)
Net cash paid for acquisitions					13,530	45,023
Supplemental disclosure of non-cash investing activities:
Capital expenditures included in accounts payable and accrued expenses and other liabilities					$ 1,085	$ 283

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (130,896)	$ (171,526)	$ (354,049)	$ (192,155)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	1. Organization and Basis of Presentation Description of Business and Organization Definitive Healthcare Corp. (the “Company”) was formed on May 5, 2021 as a Delaware corporation to facilitate an initial public offering (“IPO”) and other related transactions to carry on the business of AIDH TopCo, LLC (“Definitive OpCo”). Following consummation of the Reorganization Transactions as described below, Definitive OpCo became a subsidiary of Definitive Healthcare Corp. The Company, through its operating subsidiaries, provides comprehensive and up-to-date hospital and healthcare-related information and insight across the entire healthcare continuum via a multi-tenant software-as-a-service (“SaaS”) platform which combines proprietary and public sources to deliver insights. The Company is headquartered in Framingham, Massachusetts. In connection with the IPO, the Company completed the following transactions (the “Reorganization Transactions”). Definitive OpCo entered into an amended and restated limited liability company agreement (the “Amended LLC Agreement”) pursuant to which members of Definitive OpCo prior to the IPO who continued to hold limited liability company interests (“LLC Units”) in Definitive OpCo following the consummation of the Reorganization Transactions acquired the right to require Definitive OpCo to redeem all or a portion of their LLC Units for newly issued shares of Class A Common Stock on a one-for-one basis. Until redeemed or exchanged, each LLC Unit is paired with one share of Definitive Healthcare Corp. Class B Common Stock. The total shares of Class B Common Stock outstanding is equal to the number of vested LLC Units outstanding, excluding LLC Units held by the Company. Unvested LLC Units are paired with Class B Common Stock, which are issued but do not have voting rights and are deemed not outstanding until the corresponding LLC Units have vested. Certain entities treated as corporations for U.S. federal income tax purposes that held LLC Units (individually, a “Blocker Company” and collectively, the “Blocker Companies”) each merged with a merger subsidiary of Definitive Healthcare Corp., and subsequently merged into Definitive Healthcare Corp. (the “Mergers”). The former shareholders of the Blocker Companies collectively received a number of shares of Class A Common Stock in the Mergers equal to the number of LLC Units held by the Blocker Companies prior to the Mergers. Following the Reorganization Transactions, Definitive Healthcare Corp. became a holding company, with its sole material asset being a controlling equity interest in Definitive OpCo. Definitive Healthcare Corp. operates and controls all of the business and affairs of Definitive OpCo, and through Definitive OpCo and its subsidiaries, conducts its business. Accordingly, Definitive Healthcare Corp. consolidates the financial results of Definitive OpCo, and reports the noncontrolling interests of unexchanged LLC Unit holders on its unaudited condensed consolidated financial statements. In connection with the Reorganization Transactions and the IPO, Definitive Healthcare Corp entered into a tax receivable agreement. See Note 15. Income Taxes . Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and in conformity with rules applicable to quarterly financial information. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative nongovernmental GAAP as found in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). The unaudited condensed consolidated financial statements as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023 are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2023. All adjustments, consisting of normal recurring adjustments, except as otherwise noted, considered, in the opinion of management, necessary for a fair presentation of the unaudited condensed consolidated financial statements for these interim periods have been included. Refer to Note 2. Summary of Significant Accounting Policies in the notes to the consolidated financial statements in the 2023 Form 10-K for the Company’s significant accounting policies and estimates. Use of Estimates in the Preparation of Financial Statements The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. These estimates include, but are not limited to, revenue recognition, allowance for doubtful accounts, contingencies, valuations, useful lives of intangible assets acquired in business combinations, equity-based compensation, and income taxes. Actual results could differ from those estimates. Recently Issued Accounting Pronouncements Not Yet Adopted In November 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. These disclosures are required for entities with a single reportable segment. ASU 2023-07 is effective for annual filings for the Company’s fiscal year beginning January 1, 2024, and interim filings for the fiscal year beginning January 1, 2025, and should be applied on a retrospective basis to all periods presented. The Company is currently evaluating the effect of adopting ASU 2023-07 on its unaudited condensed consolidated financial statement disclosures. No other new accounting pronouncements issued or effective during the first nine months of the current year have had, or are expected to have, a material impact on the Company’s unaudited condensed consolidated financial statements.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2024
Business Combinations [Abstract]
Acquisitions	2. Acquisitions Carevoyance On January 16, 2024, the Company completed the purchase of assets comprising the Carevoyance business line of H1 Insights, Inc. (“Carevoyance”), a product that helps medical technology (“MedTech”) customers to improve segmentation, targeting, and prospect engagement, for $ 13.7 million in cash consideration. The Carevoyance assets meet the definition of a business and accordingly, the Company has accounted for the Carevoyance transaction under the acquisition method. The assets acquired and liabilities assumed were recorded at their estimated fair values and the results of operations were included in the Company’s consolidated results prospectively from the acquisition date. The purchase price allocations for the Carevoyance acquisition are provisional and are based on the information that was available as of the acquisition date to estimate the fair values of assets acquired and liabilities assumed. The Company is gathering and reviewing additional information necessary to finalize the values assigned to the acquired assets and liabilities assumed, as well as acquired identified intangible assets and goodwill. Therefore, the provisional measurements of fair values reported as of September 30, 2024 are subject to change. The Company is expected to finalize the purchase price allocations as soon as practicable, but no later than one year from the acquisition date. Acquisition-date fair values of assets and liabilities pertaining to this business combination have been allocated as follows: (in thousands) Purchase price allocation: Preliminary Accounts receivable $ 605 Intangible assets 7,000 Deferred revenue ( 987 ) Total assets acquired and liabilities assumed 6,618 Goodwill 7,057 Purchase price $ 13,675 As a result of the Carevoyance acquisition, the Company recorded goodwill, developed technology, customer relationships, and tradename of $ 7.1 million, $ 6.8 million, $ 0.2 million, and $ 0.1 million, respectively, as of the acquisition date. The goodwill recognized includes the fair value of the assembled workforce, which is not recognized as an intangible asset separable from goodwill, and any expected synergies gained through the acquisition. The Company determined that the goodwill resulting from the acquisition is deductible for tax purposes. All goodwill has been allocated to the Company’s one reportable segment. The developed technology represents Carevoyance’s proprietary solutions that are designed to assist MedTech customers with improving segmentation, targeting, and prospect engagement. The Company used the income approach, specifically the multi-period excess earnings method, to determine the value of developed technology. Significant assumptions include an obsolescence factor, tax rate, and discount rate. The developed technology was valued at $ 6.8 million and is amortized using the economic value method, which represents the pattern of cash flows over the estimated 7-year life of this asset. Customer relationships represent the estimated fair value of the underlying relationships with the acquired entity’s business customers. The Company valued customer relationships using the income approach, specifically the multi-period excess earnings method. Significant assumptions include estimated attrition rates, discount rates, and tax rates reflecting the different risk profiles of the asset depending upon the acquisition. The value assigned to customer relationships is $ 0.2 million and is amortized using the straight-line method over the estimated remaining useful life of 5 years . The tradename represents the estimated fair value of the registered trade name associated with the Carevoyance corporate brand. The Company estimated the fair value of the trademark using a relief from royalty method of the income approach. Significant assumptions include forecast of royalty rate, tax rate, and discount rate. The trademark was valued at $ 0.1 million and is amortized using the straight-line method over the estimated remaining useful life of 2 years . In total, intangible assets acquired in the Carevoyance acquisition are estimated to be amortized over a weighted average of 6.9 years. See Note 7. Goodwill and Intangible Assets for the estimated total intangible amortization expense during the next five years. Pro forma results of operation for this acquisition have not been presented because the effects were not material to the Company’s unaudited condensed consolidated financial results. Populi, Inc. On July 21, 2023, the Company completed the acquisition of Populi, Inc. (“Populi”), a provider-focused data and analytics company that works with healthcare organizations to optimize physician relationships, reduce network leakage, and expand market share, for total estimated consideration of $ 54.1 million, consisting of approximately $ 46.4 million of cash paid at closing, $ 0.1 reimbursement from sellers for working capital adjustments, and up to $ 28.0 million of contingent consideration, with an initial estimated fair value of $ 7.8 million. The contingent consideration relates to earn-out payments that may be paid subject to meeting certain revenue metrics during calendar years 2024 and 2025. In addition to the purchase consideration and pursuant to holdback agreements with certain key Populi employees, the Company agreed to pay $ 4.8 million to certain key Populi employees in quarterly installments beginning on December 31, 2023, and continuing through September 30, 2025. The payout of the holdback is subject to continued employment, and therefore recognized as compensation expense over the requisite service period as a component of transaction, integration and restructuring expenses in the accompanying unaudited condensed consolidated statements of operations. The assets acquired and liabilities assumed were recorded at their estimated fair values and the results of operations were included in the Company’s consolidated results as of the acquisition date. The consideration transferred for the transaction is summarized as follows: (in thousands) Cash consideration paid at closing $ 46,446 Working capital adjustment ( 145 ) Contingent consideration 7,800 Purchase price $ 54,101 The contingent consideration is based on the achievement of certain revenue metrics during the two-year period following the acquisition date, with potential earn-out payouts ranging from $ 0 to $ 28.0 million. The Company estimated the fair value of the contingent consideration to be $ 7.8 million as of July 21, 2023, based on the estimated achievement of the revenue metrics and time to payment. The contingent consideration was recorded in Other liabilities in the accompanying unaudited condensed consolidated balance sheets as of September 30, 2024. Refer to Note 11. Fair Value Measurements . The Company finalized the purchase price allocations of the Populi acquisition during the first quarter of 2024. Acquisition-date fair values of assets and liabilities pertaining to this business combination have been allocated as follows: (in thousands) Purchase price allocation: Preliminary, as originally reported Measurement period adjustments As adjusted Cash $ 1,423 $ — $ 1,423 Accounts receivable 2,662 — 2,662 Prepaid expenses and other assets 153 — 153 Property and equipment 42 — 42 Intangible assets 22,830 ( 500 ) 22,330 Accounts payable and accrued expenses ( 3,316 ) — ( 3,316 ) Deferred revenue ( 4,010 ) — ( 4,010 ) Other liabilities ( 2,354 ) ( 576 ) ( 2,930 ) Total assets acquired and liabilities assumed 17,430 ( 1,076 ) 16,354 Goodwill 36,652 1,095 37,747 Purchase price $ 54,082 $ 19 $ 54,101 As a result of the Populi acquisition, the Company recorded goodwill, developed software, customer relationships, and tradename of $ 37.7 million, $ 21.4 million, $ 0.8 million, and $ 0.1 million, respectively, as of the acquisition date. The goodwill recognized includes the fair value of the assembled workforce, which is not recognized as an intangible asset separable from goodwill, and any expected synergies gained through the acquisition. The Company determined that the goodwill resulting from the acquisition is not deductible for tax purposes. All goodwill has been allocated to the Company’s one reportable segment. The developed software represents Populi’s proprietary solutions that are designed to assist organizations in optimizing physician relationships, reducing network leakage, and expanding market share. The Company used the income approach, specifically the multi-period excess earnings method, to determine the value of developed software. Significant assumptions include an obsolescence factor, tax rate, and discount rate. The developed software was valued at $ 21.4 million and is amortized using the economic value method, which represents the pattern of cash flows over the estimated 7-year life of this asset. Customer relationships represent the estimated fair value of the underlying relationships with the acquired entity’s business customers. The Company valued customer relationships using the income approach, specifically the multi-period excess earnings method. Significant assumptions include estimated attrition rates, discount rates, and tax rates reflecting the different risk profiles of the asset depending upon the acquisition. The value assigned to customer relationships is $ 0.8 million and is amortized using the straight-line method over the estimated remaining useful life of 15 years . The tradename represents the estimated fair value of the registered trade name associated with the Populi corporate brand. The Company estimated the fair value of the trademark using a relief from royalty method of the income approach. Significant assumptions include forecast of royalty rate, tax rate, and discount rate. The trademark was valued at $ 0.1 million and is amortized using the straight-line method over the estimated remaining useful life of 1 year . In total, intangible assets acquired in the Populi acquisition are estimated to be amortized over a weighted average of 7.2 years. See Note 7. Goodwill and Intangible Assets for the estimated total intangible amortization expense during the next five years. In connection with the acquisition, the Company recognized acquisition related costs of $ 0.6 million and $ 1.7 million for the three and nine months ended September 30, 2024, respectively, which were recorded within t ransaction, integration, and restructuring expenses in the accompanying unaudited condensed consolidated statements of operations. Unaudited Pro Forma Supplementary Data as if the Populi acquisition had occurred on January 1, 2023: Three Months Ended Nine Months Ended September 30, 2023 (in thousands) Revenue $ 66,225 $ 189,697 Net loss $ ( 248,940 ) $ ( 280,870 ) These pro forma results have been prepared for comparative purposes only and do not purport to be indicative of the operating results of the Company that would have been achieved had the acquisition actually taken place on January 1, 2023. In addition, these results are not intended to be a projection of future results and do not reflect events that may occur after the acquisition, including but not limited to revenue enhancements, cost savings or operating synergies that the combined Company may achieve as a result of the acquisition .

Revenue

Revenue	9 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenue	3. Revenue The Company disaggregates revenue from its arrangements with customers by type of service as it believes these categories best depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. The following table represents a disaggregation of revenue from arrangements with customers for the three and nine months ended September 30, 2024 and 2023, respectively: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Subscription services $ 60,897 $ 62,568 $ 184,645 $ 180,358 Professional services 1,800 2,757 5,269 5,125 Total revenue $ 62,697 $ 65,325 $ 189,914 $ 185,483 Deferred Contract Costs A summary of the activity impacting the deferred contract costs for the nine months ended September 30, 2024 and the year ended December 31, 2023 is presented below: (in thousands) Nine Months Ended September 30, 2024 Twelve Months Ended December 31, 2023 Balance at beginning of period $ 30,810 $ 24,983 Costs amortized ( 11,463 ) ( 12,963 ) Additional amounts deferred 8,275 18,790 Balance at end of period 27,622 30,810 Classified as: Current 13,486 13,490 Non-current 14,136 17,320 Total deferred contract costs (deferred commissions) $ 27,622 $ 30,810 Contract Liabilities A summary of the activity impacting deferred revenue balances during the nine months ended September 30, 2024 and for the year ended December 31, 2023 is presented below: (in thousands) Nine Months Ended September 30, 2024 Twelve Months Ended December 31, 2023 Balance at beginning of period $ 97,386 $ 99,928 Revenue recognized ( 189,914 ) ( 251,415 ) Additional amounts deferred 178,768 248,873 Balance at end of period $ 86,240 $ 97,386 Remaining Performance Obligations Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes unearned revenue and unbilled amounts that will be invoiced and recognized as revenue in future periods. Transaction price allocated to remaining performance obligations is influenced by several factors, including seasonality, the timing of renewals, and disparate contract terms. The Company’s backlog represents installment billings for periods beyond the current billing cycle. The majority of the Company’s noncurrent remaining performance obligations will be recognized in the next 13 to 36 months. The remaining performance obligations consisted of the following: (in thousands) September 30, December 31, Current $ 163,692 $ 187,331 Non-current 81,181 89,636 Total $ 244,873 $ 276,967

Short-Term Investments

Short-Term Investments	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Short-Term Investments	4. Short-Term Investments Short-term investments classified as available-for-sale consisted of the following: September 30, 2024 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term investments: US Treasuries $ 25,402 $ 9 $ — $ 25,411 Commercial paper 109,143 137 ( 3 ) 109,277 Certificates of deposit 33,055 36 — 33,091 Total short-term investments $ 167,600 $ 182 $ ( 3 ) $ 167,779 December 31, 2023 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term investments: US Treasuries $ 62,486 $ 20 $ ( 45 ) $ 62,461 Corporate Bonds 2,314 10 — 2,324 Commercial Paper 94,269 85 ( 18 ) 94,336 Certificates of Deposit 17,954 19 ( 2 ) 17,971 Total short-term investments $ 177,023 $ 134 $ ( 65 ) $ 177,092 All short-term investments had stated maturity dates of less than one year. Included in the amortized cost as of September 30, 2024 and December 31, 2023 is net accumulated accretion of $ 1.8 million and $ 2.8 million, respectively. Interest accretion on short-term investments was $ 1.6 million and $ 2.1 million during the three months ended September 30, 2024 and 2023 , respectively, and $ 5.4 million and $ 5.8 million during the nine months ended September 30, 2024 and 2023 , respectively.

Accounts Receivable, Net

Accounts Receivable, Net	9 Months Ended
	Sep. 30, 2024
Receivables [Abstract]
Accounts Receivable, Net	5. Accounts Receivable, Net Accounts receivable, net consisted of the following: (in thousands) September 30, December 31, Accounts receivable $ 37,640 $ 60,206 Unbilled receivable 499 1,346 38,139 61,552 Less: allowance for credit losses ( 2,385 ) ( 2,303 ) Accounts receivable, net $ 35,754 $ 59,249

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	6. Property and Equipment, Net Property and equipment, net consisted of the following: (in thousands) September 30, December 31, Computers and software $ 7,813 $ 6,921 Furniture and equipment 907 1,172 Leasehold improvements 1,832 2,338 Construction and software development in process 142 — 10,694 10,431 Less: accumulated depreciation and amortization ( 6,990 ) ( 5,960 ) Property and equipment, net $ 3,704 $ 4,471 Depreciation and amortization expense associated with property and equipment was $ 0.5 million and $ 0.4 million for the three months ended September 30, 2024 and 2023 , respectively, and $ 1.7 million and $ 1.3 million for the nine months ended September 30, 2024 and 2023, respectively. During the second quarter of 2024, the Company consolidated certain leased office space at its corporate headquarters and, as a result, recorded an impairment charge of $ 1.0 million, comprised of $ 0.7 million related to the operating lease right-of-use asset, and $ 0.3 million related to leasehold improvements. These non-cash charges were recognized within transaction, integration, and restructuring expenses in the Company’s unaudited condensed consolidated statements of operations. The Company also recorded accelerated depreciation of furniture and fixtures of $ 0.1 million and disposed of $ 1.0 million of fully depreciated property and equipment in connection with the office consolidation during the second quarter of 2024.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	7. Goodwill and Intangible Assets The carrying amounts of goodwill and intangible assets, as of September 30, 2024 and December 31, 2023, consisted of the following: September 30, 2024 (in thousands) Gross Accumulated Net Carrying Finite-lived intangible assets: Customer relationships $ 410,390 $ ( 188,358 ) $ 222,032 Developed technologies 85,191 ( 41,157 ) 44,034 Tradenames 36,121 ( 11,095 ) 25,026 Database 51,457 ( 48,019 ) 3,438 Total finite-lived intangible assets 583,159 ( 288,629 ) 294,530 Goodwill 490,343 — 490,343 Total goodwill and intangible assets $ 1,073,502 $ ( 288,629 ) $ 784,873 December 31, 2023 (in thousands) Gross Accumulated Net Carrying Finite-lived intangible assets: Customer relationships $ 410,210 $ ( 163,586 ) $ 246,624 Developed technologies 78,434 ( 33,769 ) 44,665 Tradenames 36,062 ( 9,379 ) 26,683 Database 50,221 ( 45,072 ) 5,149 Total finite-lived intangible assets 574,927 ( 251,806 ) 323,121 Goodwill 1,075,080 — 1,075,080 Total goodwill and intangible assets $ 1,650,007 $ ( 251,806 ) $ 1,398,201 Amortization expense associated with finite-lived intangible assets wa s $ 12.5 m illion and $ 12.6 million for the three months ended September 30, 2024 and 2023 , respectively, of which $ 3.6 million and $ 3.2 million was included in cost of revenue for each respective period. Amortization expense associated with finite-lived intangible assets wa s $ 36.8 m illion and $ 37.4 million for the nine months ended September 30, 2024 and 2023 , respectively, of which $ 10.3 million and $ 9.7 million was included in cost of revenue for each respective period. Estimated total intangible amortization expense during the next five years and thereafter is as follows: (in thousands) 2024, excluding the nine months ended September 30, 2024 $ 12,213 2025 47,425 2026 41,250 2027 35,045 2028 30,778 Thereafter 127,819 Total $ 294,530 The Company determined it had one reporting unit. Goodwill Impairment Goodwill and acquired intangible assets are initially recorded at fair value and tested periodically for impairment. The Company estimates the fair value of these assets using primarily unobservable inputs, which are considered Level 3 fair value measurements as defined in Note 11. Fair Value Measurements . The Company performs an impairment test of goodwill during the fourth quarter of each fiscal year and more frequently if indicators of potential impairment arise. Though the Company traditionally performs its annual impairment assessment in the first month of the fourth quarter of each calendar year, during the second and third quarters of 2024, the Company experienced declines in its market capitalization as a result of sustained decreases in the Company’s stock price, which represented triggering events in both periods, requiring management to perform a quantitative goodwill impairment test as of the end of each respective reporting period. As a result of the impairment tests, the Company determined that the fair value of its single reporting unit was lower than its carrying value and, accordingly, recorded non-cash, pretax, goodwill impairment charges of $ 228.2 million and $ 363.6 million during the three months ended September 30, 2024 and June 30, 2024, respectively. The goodwill impairment charges did not affect the Company’s liquidity or the financial covenants in its outstanding debt agreement. In calculating the goodwill impairment charges, the Company estimated the fair value of its single reporting unit based on its market capitalization and an appropriate control premium. Market capitalization is determined by multiplying the number of shares of Class A Common Stock outstanding by the market price of its Class A Common Stock. The control premium, or the amount paid by a new controlling shareholder for the benefits resulting from synergies and other potential benefits derived from controlling the acquired company, is determined by utilizing data from publicly available premium studies for similarly situated public company transactions. A goodwill impairment loss is recognized for the difference between the carrying value of the reporting unit and the fair value. As of and for the periods ended September 30, 2024 and December 31, 2023, goodwill consisted of the following: (in thousands) Nine Months Ended Twelve Months Ended Goodwill, gross - beginning of period $ 1,362,480 $ 1,324,733 Accumulated impairment losses ( 287,400 ) — Goodwill, net - beginning of period 1,075,080 1,324,733 Goodwill acquired during period 7,057 37,747 Goodwill impairment loss ( 591,794 ) ( 287,400 ) Goodwill, net - end of period $ 490,343 $ 1,075,080 (in thousands) Nine Months Ended Twelve Months Ended Goodwill, gross - end of period $ 1,369,537 $ 1,362,480 Accumulated impairment losses ( 879,194 ) ( 287,400 ) Goodwill, net - end of period $ 490,343 $ 1,075,080 The Company also considered its intangible assets with finite useful lives, which are amortized over their estimated useful lives, generally on a straight-line basis. These assets are reviewed for impairment when facts or circumstances indicate that the carrying values may not be recoverable. The Company experienced two separate triggering events in the nine months ended September 30, 2024 resulting from declines in the Company’s market capitalization driven by sustained decreases in the Company’s stock price. In each case, the Company’s intangible assets were reviewed for impairment. Based on quantitative and qualitative analyses performed, management concluded the assets were recoverable and no impairment charges were recorded as a result of either triggering event.

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	9 Months Ended
	Sep. 30, 2024
Accounts Payable and Accrued Liabilities, Current [Abstract]
Accrued Expenses and Other Liabilities	8. Accrued Expenses and Other Liabilities Accrued expenses and other liabilities consisted of the following: (in thousands) September 30, December 31, Payroll and payroll-related $ 10,516 $ 12,805 Tax receivable agreement, current portion 13,075 20,095 Contingent consideration, current — 1,602 Sales, franchise, and other taxes 6,321 9,526 Other 5,839 7,501 Accrued expenses and other liabilities $ 35,751 $ 51,529 On January 3, 2024, the Company committed to a restructuring plan (the “2024 Restructuring Plan”) intended to reduce operating costs, improve operating margins, and continue advancing the Company’s ongoing commitment to profitable growth. The 2024 Restructuring Plan provided for a reduction of the Company’s current workforce by approximately 150 people. During the three and nine months ended September 30, 2024, the Company incurred restructuring and related charges of $ 0.2 million and $ 8.0 million, respectively, consisting of severance payments, employee benefits, and related cash expenses. As of September 30, 2024 , $ 0.5 million of severance and separation benefits is included in accrued expenses and other liabilities in the unaudited condensed consolidated balance sheets and the Company expects these payments will be made over the next six to nine months. The Company does not expect to incur any additional material charges associated with the 2024 Restructuring Plan. The following table sets forth the activity in the Company’s liabilities resulting from the 2024 Restructuring Plan: (in thousands) Employee termination costs Balance at December 31, 2023 $ 122 Charges incurred 8,009 Cash payments made ( 7,677 ) Balance at September 30, 2024 $ 454

Long-Term Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2024
Long-Term Debt, Unclassified [Abstract]
Long-Term Debt	9. Long-Term Debt Long-term debt consisted of the following as of September 30, 2024 and December 31, 2023, respectively: September 30, 2024 (in thousands) Principal Unamortized debt Total debt, 2021 Term Loan $ 247,500 $ ( 1,082 ) $ 246,418 Less: current portion of long-term debt 13,750 Long-term debt $ 232,668 December 31, 2023 (in thousands) Principal Unamortized debt Total debt, 2021 Term Loan $ 257,813 $ ( 1,496 ) $ 256,317 Less: current portion of long-term debt 13,750 Long-term debt $ 242,567 During the nine months ended September 30, 2024, the Company repaid $ 10.3 million in outstanding principal of the 2021 Term Loan (as defined below). 2021 Credit Agreement In September 2021, DH Holdings entered into a credit agreement (the “2021 Credit Agreement” ) with Bank of America, N.A., as administrative agent, the other lenders party thereto and the other parties specified therein. The 2021 Credit Agreement provides for (i) a $ 275.0 million term loan A facility (the “2021 Term Loan” ) and (ii) a $ 75.0 million revolving credit facility (the “2021 Revolving Line of Credit” and, together with the 2021 Term Loan, collectively, the “2021 Credit Facilities” ), the proceeds of which were used to repay a portion of the indebtedness outstanding under a previous credit agreement. Both the 2021 Term Loan and the 2021 Revolving Line of Credit mature on September 17, 2026 . The 2021 Credit Facilities include customary affirmative, negative, and financial covenants. The 2021 Credit Facilities are guaranteed by all of DH Holdings ’ wholly owned domestic restricted subsidiaries and AIDH Buyer, LLC, a Delaware limited liability company and the direct parent company of DH Holdings, in each case, subject to customary exceptions, and are secured by a lien on substantially all of the assets of DH Holdings and the guarantors, including a pledge of the equity of DH Holdings, in each case, subject to customary exceptions. The 2021 Term Loan is subject to annual amortization of principal, payable in equal quarterly installments on the last day of each fiscal quarter, commencing on December 31, 2021 (the “Initial Amortization Date” ), equal to approximately 2.5% per annum of the principal amount of the term loans in the first year and second year after the Initial Amortization Date and approximately 5.0% per annum of the principal amount of the term loans in the third year, fourth year, and fifth year after the Initial Amortization Date. A balloon payment of approximately $ 220.0 million will be due at the maturity of the 2021 Term Loan. There wa s $ 247.5 million outstanding on the 2021 Term Loan at September 30, 2024. DH Holdings is required to pay the lenders under the 2021 Credit Agreement an unused commitment fee of between 0.25 % and 0.30 % per annum on the undrawn commitments under the 2021 Revolving Line of Credit, depending on the total net leverage ratio, quarterly in arrears. The expense is included in interest expense in the statements of operations. There was no outstanding balance on the 2021 Revolving Line of Credit at September 30, 2024 . In September 2023, the lessor of the Company’s corporate headquarters transitioned from one entity to another. As a result, in December 2023, in lieu of a security deposit, the Company provided a standby letter of credit of $ 0.6 million, which reduced the amount available under our revolving credit facility to $ 74.4 million as of September 30, 2024. For both the 2021 Term Loan and 2021 Revolving Line of Credit, DH Holdings may elect from several interest rate options based on the Term Secured Overnight Financing Rate (“SOFR”) or the Base Rate plus an applicable margin. The applicable margin is based on the total leverage ratio beginning in the fiscal year ended December 31, 2022. As of September 30, 2024 , the effective interest rate was 6.70 %. In connection with the 2021 Credit Agreement, the Company capitalized financing costs totaling $ 3.5 million, $ 2.8 million for the 2021 Term Loan facility and $ 0.8 million for the 2021 Revolving Line of Credit. The financing costs associated with the 2021 Term Loan facility are recorded as a contra-debt balance in Term loan, net of current portion in the unaudited condensed consolidated balance sheets and are amortized over the remaining life of the loan using the effective interest method. The financing costs associated with the 2021 Revolving Line of Credit are recorded in other assets in the unaudited condensed consolidated balance sheet are amortized over the life of the arrangement. At September 30, 2024 and December 31, 2023 , the unamortized financing costs were $ 0.3 million and $ 0.4 million, respectively.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	9 Months Ended
	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	10. Derivative Instruments and Hedging Activities Risk Management Objective of Using Derivatives The Company is exposed to risks from changes in interest rates related to the 2021 Term Loan (See Note 9. Long-Term Debt ). The Company uses derivative financial instruments, specifically, interest rate swap contracts, in order to manage its exposure to interest rate movements. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Our primary objective in holding derivatives is to reduce the volatility of cash flows associated with changes in interest rates. The Company does not enter into derivative transactions for speculative or trading purposes. Cash Flow Hedges of Interest Rate Risk The Company entered into two interest rate swap agreements, effective on March 31, 2022. Until October 31, 2022, the counterparties to each of the agreements paid the Company interest at a floating rate on the notional amounts based on the one-month USD-LIBO swap rate. On October 31, 2022, in conjunction with the amendment to the 2021 Credit Agreement (See Note 9. Long-Term Debt ), the Company amended the two interest rate swap agreements to replace the LIBO rate with Term SOFR. As a result, subsequent to October 31, 2022, the counterparties paid and will continue to pay interest at a floating rate based on Term SOFR. As of September 30, 2024 , the two outstanding interest rate swap agreements each had a notional value of $ 61.9 million with fixed interest rate s of 1.90650 % and 1.90900 %. Inter est payments under the swaps are made monthly on a net settlement basis. The Company has not recorded any amounts due to ineffectiveness for the period ended September 30, 2024 or year ended December 31, 2023 . The notional value of each interest rate swap agreement is expected to match the corresponding principal amount of a portion of our borrowings under the 2021 Term Loan. The swap agreements mature on March 31, 2025 . The derivative interest rate swaps are designated and qualify as cash flow hedges. Consequently, the change in the estimated fair value of the effective portion of the derivative is recognized in accumulated other comprehensive income (“AOCI”) on our consolidated balance sheets and reclassified to interest expense, net, when the underlying transaction has an impact on earnings. The Company expects to recognize approximately $ 1.4 million of net pre-tax gains from accumulated other comprehensive income as a reduction of interest expense in the next twelve months associated with its interest rate swaps. The Company recognizes derivative instruments and hedging activities on a gross basis as either assets or liabilities on the Company’s consolidated balance sheets and measures them at fair value. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the earnings effect of the hedged forecasted transactions in a cash flow hedge. To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The fair values of the interest rate swaps and their respective locations in our unaudited condensed consolidated balance sheets at September 30, 2024 and December 31, 2023 were as follows: (in thousands) Description Balance Sheet Location September 30, 2024 December 31, 2023 Short-term derivative asset Prepaid expenses and other assets $ 1,426 $ 3,426 Long-term derivative asset Other assets — 509

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	11. Fair Value Measurements ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), defines fair value as the price that would be received for an asset, or paid to transfer a liability, in an orderly transaction between market participants on the measurement date, and establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value as follows: Level 1 – Observable inputs (unadjusted) that reflect unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 – Other inputs that are directly or indirectly observable in the marketplace. Level 3 – Unobservable inputs that are supported by little or no market activity, including the Company’s own assumptions in determining fair value. The Company’s financial assets and liabilities subject to the three-level fair value hierarchy consist principally of cash and equivalents, short-term investments, accounts receivable, accounts payable, long-term and short-term debt, and contingent consideration payable. The estimated fair value of cash included in cash and cash equivalents, accounts receivable, and accounts payable approximates their carrying value due to due to their short maturities (less than 12 months). Debt The Company’s short- and long-term debt are recorded at their carrying values in the unaudited condensed consolidated balance sheets, which may differ from their respective fair values. The estimated fair values of the Company’s short- and long-term debt approximate their carrying values as of September 30, 2024 and December 31, 2023, based on interest rates currently available to the Company for similar borrowings. Money market funds (included in cash and cash equivalents) Money market funds are recorded at fair value using quoted market prices in active markets and are classified as Level 1 in the fair value hierarchy. Short-term investments The Company estimates the fair values of investments in U.S. treasuries, agency bond securities, commercial paper, and certificates of deposit using level 2 inputs, taking into consideration valuations obtained from a third-party pricing service. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, market yield curves, benchmark securities, prepayment/default projections based on historical data, and other observable inputs. Derivative financial instruments Currently, the Company uses interest rate swaps to manage interest rate risk. The valuation of these instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves, and implied volatilities. To comply with the provisions of ASC 820, the Company incorporates credit valuation adjustments to appropriately reflect both its own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements. Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by the Company and its counterparties. The Company has determined that the significance of the impact of the credit valuation adjustments made to its derivative contracts, which determination was based on the fair value of each individual contract, was not significant to the overall valuation. As a result, all of its derivatives held as of September 30, 2024 and December 31, 2023 were classified as Level 2 in the fair value hierarchy. Contingent consideration The deferred consideration resulting from the acquisition of Populi in the third quarter of 2023, which is subject to meeting certain revenue metrics during calendar years 2024 and 2025, is measured at fair value on a recurring basis. The fair value was estimated based on the present value of the amount expected to be paid at the end of the measurement period. At September 30, 2024, the fair value of the contingent consideration associated with this acquisition was estimated to be $ 5.5 million and was included in other long-term liabilities on the unaudited condensed consolidated balance sheets. The contingent consideration that resulted from the earnout associated with the acquisition of Analytical Wizards Inc. in February 2022, which was included in accrued expenses and other liabilities in the condensed consolidated balance sheets as of December 31, 2023, was paid during the nine months ended September 30, 2024. Earnout liabilities are classified within Level 3 in the fair value hierarchy because the methodology used to develop the estimated fair value includes significant unobservable inputs reflecting management’s own assumptions. The table below presents a reconciliation of earnout liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3): (in thousands) Nine Months Ended September 30, 2024 Twelve Months Ended December 31, 2023 Balance at beginning of period $ 10,352 $ 2,250 Additions — 7,800 Net change in fair value and other adjustments ( 3,240 ) 302 Payments ( 1,602 ) — Balance at end of period $ 5,510 $ 10,352 Non-recurring fair value measurements Certain assets and liabilities, including property, plant, and equipment, lease right-of-use assets, goodwill, and other intangible assets, are measured at fair value on a non-recurring basis. These assets are remeasured when the derived fair value is below the carrying value on the Company’s unaudited condensed consolidated balance sheet. For these assets, the Company does not periodically adjust carrying value to fair value except in the event of impairment. When impairment has occurred, the Company measures the required charges and adjusts the carrying value as discussed in Note 2. Summary of Significant Accounting Policies of the notes to the consolidated financial statements in the Company’s 2023 Form 10-K. At September 30, 2024 and December 31, 2023, assets and liabilities measured at fair value on a recurring basis were as follows: September 30, 2024 (in thousands) Total Level 1 Level 2 Level 3 Assets: Cash and cash equivalents: Money market funds $ 107,711 $ 107,711 $ — $ — Short-term investments: U.S. Treasuries 25,411 — 25,411 — Commercial paper 109,277 — 109,277 — Certificates of deposit 33,091 — 33,091 — Prepaid expenses and other assets: Interest rate swap contracts 1,426 — 1,426 — Liabilities: Contingent consideration 5,510 — — 5,510 December 31, 2023 (in thousands) Total Level 1 Level 2 Level 3 Assets: Cash and cash equivalents: Money market funds $ 87,869 $ 87,869 $ — $ — Commercial paper (maturities less than 90 days) 4,227 — 4,227 — Certificates of deposit (maturities less than 90 days) 1,000 — 1,000 — Short-term investments: U.S. treasuries 62,461 — 62,461 — Corporate bonds 2,324 — 2,324 — Commercial paper 94,336 — 94,336 — Certificates of deposit 17,971 — 17,971 — Prepaid expenses and other assets: Interest rate swap contracts 3,426 — 3,426 — Other assets: Interest rate swap contracts 509 — 509 — Liabilities: Contingent consideration 10,352 — — 10,352 At September 30, 2024 and December 31, 2023 , except for the contingent consideration noted above, the estimated fair values of all of the Company’s financial assets and liabilities subject to the three-level fair value hierarchy approximated their carrying values due to their short-term maturities (less than 12 months).

Noncontrolling Interest

Noncontrolling Interest	9 Months Ended
	Sep. 30, 2024
Noncontrolling Interest [Abstract]
Noncontrolling Interest	12. Noncontrolling Interest Definitive Healthcare Corp. operates and controls all of the business and affairs of Definitive OpCo, and through Definitive OpCo and its subsidiaries, conducts its business. Accordingly, Definitive Healthcare Corp. consolidates the financial results of Definitive OpCo, and reports the noncontrolling interests of its consolidated subsidiaries on its unaudited condensed consolidated financial statements based on the LLC Units held by Continuing Pre-IPO LLC Members other than Definitive Healthcare Corp. Changes in Definitive Healthcare Corp.’s ownership interest in its consolidated subsidiaries are accounted for as equity transactions. As such, future redemptions or direct exchanges of LLC Units by such Continuing Pre-IPO LLC Members will result in a change in ownership and reduce or increase the amount recorded as noncontrolling interests and increase or decrease additional paid-in capital in the Company’s unaudited condensed consolidated balance sheets. During the nine months ended September 30, 2024 , 249,225 LLC Units held by Continuing Pre-IPO LLC Members were exchanged for shares of Class A Common Stock of Definitive Healthcare Corp. pursuant to the terms of the Amended LLC Agreement. In addition, 2,694,888 restricted stock units (“RSUs”) vested and 918,054 shares of Class A Common Stock were withheld to cover withholding tax obligations, resulting in the net issuance of 1,776,834 shares of Class A Common Stock of Definitive Healthcare Corp. Furthermore, 3,144,516 shares of Class A Common Stock have been repurchased and subsequently retired under a stock repurchase program authorized by the Company’s Board of Directors. Pursuant to the Definitive OpCo second amended and restated limited liability company agreement entered into in connection with the IPO, LLC Units were issued on a one-for-one basis in connection with the vesting of RSUs and LLC Units were cancelled on a one-for-one basis in connection with the repurchases of shares of the Company’s Class A Common Stock. As of September 30, 2024 and December 31, 2023, Definitive Healthcare Corp. held ownership interests in Definitive OpCo of 74.6 % and 74.9 %, respectively, and noncontrolling interests of 25.4 % and 25.1 %, respectively .

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 30, 2024
Stockholders' Equity Note [Abstract]
Accumulated Other Comprehensive Income	13. Accumulated Other Comprehensive Income The following tables summarize the changes in accumulated balances of other comprehensive income for the three and nine months ended September 30, 2024 and 2023, respectively. Three Months Ended September 30, 2024 Nine Months Ended September 30, 2024 (in thousands) Unrealized Gain (Loss) on Cash Flow Hedges Unrealized (Loss) Gain on Investments Foreign Currency Translation Adjustments Total Unrealized Gain (Loss) on Cash Flow Hedges Unrealized Gain on Investments Foreign Currency Translation Adjustments Total Beginning balance $ 1,601 $ ( 50 ) $ ( 494 ) $ 1,057 $ 2,387 $ 96 $ ( 374 ) $ 2,109 Other comprehensive (loss) income before reclassifications ( 276 ) 219 159 102 599 73 39 711 Amounts reclassified from AOCI ( 815 ) — — ( 815 ) ( 2,476 ) — — ( 2,476 ) Ending balance $ 510 $ 169 $ ( 335 ) $ 344 $ 510 $ 169 $ ( 335 ) $ 344 Three months ended September 30, 2023 Nine months ended September 30, 2023 (in thousands) Unrealized Gain (Loss) on Cash Flow Hedges Unrealized (Loss) Gain on Investments Foreign Currency Translation Adjustments Total Unrealized Gain (Loss) on Cash Flow Hedges Unrealized Loss on Investments Foreign Currency Translation Adjustments Total Beginning balance $ 4,158 $ ( 326 ) $ ( 580 ) $ 3,252 $ 4,307 $ ( 135 ) $ ( 504 ) $ 3,668 Other comprehensive income (loss) before reclassifications 505 148 ( 22 ) 631 1,710 ( 43 ) ( 98 ) 1,569 Amounts reclassified from AOCI ( 832 ) — — ( 832 ) ( 2,186 ) — — ( 2,186 ) Ending balance $ 3,831 $ ( 178 ) $ ( 602 ) $ 3,051 $ 3,831 $ ( 178 ) $ ( 602 ) $ 3,051

Stockholders' Equity and Equity

Stockholders' Equity and Equity-Based Compensation	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stockholders' Equity and Equity-Based Compensation	14. Stockholders’ Equity and Equity-Based Compensation Stock Repurchase Program In May 2024, the Company’s Board of Directors authorized a stock repurchase program of up to $ 20.0 million of the Company’s Class A Common Stock, which expires on December 31, 2024. Repurchases may be effected, from time to time, either on the open market (including pre-set trading plans), in privately negotiated transactions, and other transactions in accordance with applicable securities laws. The timing and the amount of any repurchased Class A Common Stock will be determined by the Company’s management based on its evaluation of market conditions and other factors. The repurchase program will be funded using the Company’s working capital. Any repurchased shares of Class A Common Stock will be retired. The repurchase program does not obligate the Company to acquire any particular amount of Class A Common Stock, and the repurchase program may be suspended or discontinued at any time at the Company’s discretion. As of September 30, 2024 , 3,144,516 shares of Class A Common Stock have been repurchased under the repurchase program for $ 15.0 million. Equity-Based Compensation The Company recognizes equity-based compensation expense associated with awards granted under equity incentive plans. Equity-based compensation expense is allocated to all departments based on the recipients of the compensation. A summary of the expense by line item in the unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023, respectively, is provided in the following table. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Cost of revenue $ 88 $ 276 $ 668 $ 830 Sales and marketing 829 2,728 4,786 8,297 Product development 1,218 3,236 6,928 9,566 General and administrative 4,161 5,754 18,338 16,792 Total compensation expense $ 6,296 $ 11,994 $ 30,720 $ 35,485 During the three and nine months ended September 30, 2024, the Company accelerated the vesting of 28,879 and 779,024 previously unvested time-based RSUs, respectively, along with 7,839 and 67,937 previously unvested LLC Units, respectively. Additionally, during the three and nine months ended September 30, 2024, the Company accelerated the vesting of 9,300 and 58,565 previously unvested performance-based RSUs (“PSUs”), respectively. These modifications occurred in connection with departures of certain executive-level employees. Remaining unvested shares held by the award holders were forfeited upon separation, and the modifications resulted in incremental stock-based compensation charges of approximately $ 0.1 million and $ 7.4 million during the three and nine months ended September 30, 2024, respectively.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	15. Income Taxes During the nine months ended September 30, 2024, management performed an assessment of the recoverability of deferred tax assets. Management determined, based on the accounting standards applicable to such assessment, that there was sufficient negative evidence as a result of the Company’s scheduled reversal of deferred tax liabilities and cumulative losses to conclude it was more likely than not that its deferred tax assets would not be realized and has recorded a valuation allowance against its deferred tax assets that are not more likely than not to be realized. As of September 30, 2024 and December 31, 2023 , the Company has recorded net deferred tax liabilities of $ 30.6 million and $ 67.2 million, respectively. The Company's effective tax rate was 6.8 % and 6.6 % for the three months ended September 30, 2024 and 2023, respectively, and 6.7 % and 6.7 % for the nine months ended September 30, 2024 and 2023 , respectively. The Company’s effective tax rate differs from the statutory tax rate of 21 % due to the valuation allowance recorded, foreign tax rates that differ from the U.S. statutory tax rate, and partnership income that is not taxed. The income of the Company’s subsidiaries is generally subject to corporate-level taxation, and certain of these subsidiaries have a valuation allowance whereas others do not. The effective tax rates for each period generally arise from the tax provisions for Company subsidiaries without valuation allowances, and the impact of any revaluation of deferred taxes arising from changes in the states effective tax rates. Such revaluations are caused by changes in state apportionment factors arising from fluctuations in the mix of sales, property and payroll by state, certain state tax rate changes and certain state tax incentives. Tax Receivable Agreement Pursuant to the Company’s election under Section 754 of the Internal Revenue Code (the “Code”), the Company expects to obtain an increase in its share of the tax basis in the net assets of Definitive OpCo when LLC Interests are redeemed or exchanged by other members. The Company intends to treat any redemptions and exchanges of LLC Interest as direct purchases of LLC Interests for U.S. federal income tax purposes. These increases in tax basis may reduce the amounts that would otherwise be paid in the future to various tax authorities. They may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. In connection with the IPO, the Company entered into a Tax Receivable Agreement (“TRA”) among Definitive Healthcare Corp., Definitive OpCo, and the TRA Parties and has recorded a liability under the TRA of $ 72.1 milli on and $ 147.1 million as of September 30, 2024 and December 31, 2023, respectively. During the three and nine months ended September 30, 2024 , the Company recognized a TRA remeasurement gain of $ 24.2 million and $ 68.2 million, respectively. During the three and nine months ended September 30, 2023 , the Company recognized a TRA remeasurement gain of $ 29.7 million and $ 25.0 million, respectively. Losses and gains in both periods were recognized within other income, net in the Company’s unaudited condensed consolidated statements of operations. Under the TRA, the Company generally will be required to pay to the TRA Parties 85 % of the amount of cash savings, if any, in U.S. federal, state, or local tax that the Company actually realizes directly or indirectly (or are deemed to realize in certain circumstances) as a result of (i) certain tax basis adjustments resulting from (a) acquisitions by the Company of LLC Units from pre-IPO holders in connection with the IPO, and (b) subsequent redemptions or exchanges of LLC Units by holders for Class A Common Stock or other consideration, (ii) certain tax attributes acquired by the Company from the Blocker Companies in the Reorganization Transactions, and (iii) certain payments made under the TRA. The Company expects to benefit from the remaining 15 % of any tax benefits that it may actually realize. To the extent that the Company is unable to timely make payments under the TRA for any reason, such payments generally will be deferred and will accrue interest until paid.

Loss Per Share

Loss Per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Loss Per Share	16. Loss Per Share Basic net loss per share of Class A Common Stock is computed by dividing net income attributable to Definitive Healthcare Corp. by the weighted-average number of shares of Class A Common Stock outstanding during the period, excluding unvested equity awards and subsidiary member units not exchanged. Diluted earnings per share of Class A Common Stock is calculated by dividing net income attributable to Definitive Healthcare Corp., adjusted for the assumed exchange of all potentially dilutive securities by the weighted-average number of shares of Class A Common Stock outstanding. The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted net loss per share of Class A Common Stock for the three and nine months ended September 30, 2024 and 2023 . Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Numerator: Net loss $ ( 187,824 ) $ ( 248,688 ) $ ( 506,729 ) $ ( 276,265 ) Less: Net loss attributable to noncontrolling interests ( 56,928 ) ( 77,162 ) ( 152,680 ) ( 84,110 ) Net loss attributable to Definitive Healthcare Corp. $ ( 130,896 ) $ ( 171,526 ) $ ( 354,049 ) ( 192,155 ) The following table sets forth the computation of basic and diluted net loss per share of Class A Common Stock for the three and nine months ended September 30, 2024 and 2023 (per share amounts unaudited). Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except number of shares and per share amounts) 2024 2023 2024 2023 Basic net loss per share attributable to common stockholders Numerator: Allocation of net loss attributable to Definitive Healthcare Corp. $ ( 130,896 ) $ ( 171,526 ) $ ( 354,049 ) $ ( 192,155 ) Denominator: Weighted average number of shares of Class A Common Stock outstanding 116,382,021 114,527,514 117,185,701 111,533,166 Net loss per share, basic and diluted $ ( 1.12 ) $ ( 1.50 ) $ ( 3.02 ) $ ( 1.72 ) Shares of the Company’s Class B Common Stock do not participate in the earnings or losses of Definitive Healthcare Corp. and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share of Class B Common Stock under the two-class method has not been presented. The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the period presented because their effect would have been anti-dilutive: Nine Months Ended September 30, 2024 2023 Definitive OpCo LLC Units (vested and unvested) 39,460,224 39,781,946 Restricted Stock Units 9,092,737 6,847,050

Related Parties

Related Parties	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
Related Parties	17. Related Parties The Company has engaged in revenue transactions within the ordinary course of business with entities affiliated with its Sponsors and with members of the Company’s board of directors. During each of the three months ended September 30, 2024 and 2023 , the Company recorded revenue from related parties of $ 0.3 million. During each of the nine months ended September 30, 2024 and 2023 , the Company recorded revenue from related parties of $ 0.7 million and $ 1.1 million, respectively. Receivables for related party revenue transactions amounted to $ 0.1 million and $ 0.9 million at September 30, 2024 and December 31, 2023 , respectively.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events On November 1, 2024, the Company’s Board of Directors authorized a stock repurchase program of up to $ 100.0 million of its Class A Common Stock, which expires on December 31, 2025 (the “2025 Repurchase Program”). Repurchases may be effected, from time to time, either on the open market (including pre-set trading plans), in privately negotiated transactions, and other transactions in accordance with applicable securities laws. The timing and the amount of any repurchased Class A Common Stock will be determined by the Company’s management based on its evaluation of market conditions and other factors. The Repurchase Program will be funded using the Company’s working capital. Any repurchased shares of Class A Common Stock will be retired. The Repurchase Program does not obligate the Company to acquire any particular amount of Class A Common Stock, and the Repurchase Program may be suspended or discontinued at any time at the Company’s discretion. As of November 7, 2024, no repurchases have been made pursuant to the 2025 Repurchase Program. On November 7, 2024, the Company and Advent International entered into a voting agreement, pursuant to which Advent International and its affiliated funds (“Advent”) agreed, on each matter brought to a vote at any annual or special meeting of the Company’s stockholders and in connection with any action proposed to be taken by consent of the Company’s stockholders in lieu of a meeting, to vote all shares of voting stock of the Company, or other voting or equity securities of the Company which could be issued (collectively, “Voting Securities”) beneficially owned by Advent that excee d 40.3 % of the outstanding Voting Securities of the Company (the “Excess Voting Securities”), in the same proportion as all votes cas t by stockholders other than Advent. Any Voting Securities that are not Excess Voting Securities may be voted at the discretion of Advent. On November 7, 2024, the Company announced that, following discussions regarding the scope of the role of Chief Financial Officer, Richard Booth, the Company’s Chief Financial Officer, and the Company agreed that Mr. Booth will be leaving the Company effective June 1, 2025. The Company will be commencing a search, which will include both internal and external candidates, to identify Mr. Booth’s successor prior to his departure date.

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and in conformity with rules applicable to quarterly financial information. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative nongovernmental GAAP as found in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). The unaudited condensed consolidated financial statements as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023 are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2023. All adjustments, consisting of normal recurring adjustments, except as otherwise noted, considered, in the opinion of management, necessary for a fair presentation of the unaudited condensed consolidated financial statements for these interim periods have been included. Refer to Note 2. Summary of Significant Accounting Policies in the notes to the consolidated financial statements in the 2023 Form 10-K for the Company’s significant accounting policies and estimates.
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. These estimates include, but are not limited to, revenue recognition, allowance for doubtful accounts, contingencies, valuations, useful lives of intangible assets acquired in business combinations, equity-based compensation, and income taxes. Actual results could differ from those estimates.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In November 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. These disclosures are required for entities with a single reportable segment. ASU 2023-07 is effective for annual filings for the Company’s fiscal year beginning January 1, 2024, and interim filings for the fiscal year beginning January 1, 2025, and should be applied on a retrospective basis to all periods presented. The Company is currently evaluating the effect of adopting ASU 2023-07 on its unaudited condensed consolidated financial statement disclosures. No other new accounting pronouncements issued or effective during the first nine months of the current year have had, or are expected to have, a material impact on the Company’s unaudited condensed consolidated financial statements.

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2024
Carevoyance
Business Acquisition [Line Items]
Summary of Allocation of Purchase Price to the Fair Value of Assets Acquired	The Company is expected to finalize the purchase price allocations as soon as practicable, but no later than one year from the acquisition date. Acquisition-date fair values of assets and liabilities pertaining to this business combination have been allocated as follows: (in thousands) Purchase price allocation: Preliminary Accounts receivable $ 605 Intangible assets 7,000 Deferred revenue ( 987 ) Total assets acquired and liabilities assumed 6,618 Goodwill 7,057 Purchase price $ 13,675
Populi Inc.
Business Acquisition [Line Items]
Summary of Transaction Transferred	The consideration transferred for the transaction is summarized as follows: (in thousands) Cash consideration paid at closing $ 46,446 Working capital adjustment ( 145 ) Contingent consideration 7,800 Purchase price $ 54,101
Summary of Allocation of Purchase Price to the Fair Value of Assets Acquired	Acquisition-date fair values of assets and liabilities pertaining to this business combination have been allocated as follows: (in thousands) Purchase price allocation: Preliminary, as originally reported Measurement period adjustments As adjusted Cash $ 1,423 $ — $ 1,423 Accounts receivable 2,662 — 2,662 Prepaid expenses and other assets 153 — 153 Property and equipment 42 — 42 Intangible assets 22,830 ( 500 ) 22,330 Accounts payable and accrued expenses ( 3,316 ) — ( 3,316 ) Deferred revenue ( 4,010 ) — ( 4,010 ) Other liabilities ( 2,354 ) ( 576 ) ( 2,930 ) Total assets acquired and liabilities assumed 17,430 ( 1,076 ) 16,354 Goodwill 36,652 1,095 37,747 Purchase price $ 54,082 $ 19 $ 54,101
Schedule of Business Acquisition, Pro Forma Information	Unaudited Pro Forma Supplementary Data as if the Populi acquisition had occurred on January 1, 2023: Three Months Ended Nine Months Ended September 30, 2023 (in thousands) Revenue $ 66,225 $ 189,697 Net loss $ ( 248,940 ) $ ( 280,870 )

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The following table represents a disaggregation of revenue from arrangements with customers for the three and nine months ended September 30, 2024 and 2023, respectively: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Subscription services $ 60,897 $ 62,568 $ 184,645 $ 180,358 Professional services 1,800 2,757 5,269 5,125 Total revenue $ 62,697 $ 65,325 $ 189,914 $ 185,483
Summary of Deferred Contract Costs	Deferred Contract Costs A summary of the activity impacting the deferred contract costs for the nine months ended September 30, 2024 and the year ended December 31, 2023 is presented below: (in thousands) Nine Months Ended September 30, 2024 Twelve Months Ended December 31, 2023 Balance at beginning of period $ 30,810 $ 24,983 Costs amortized ( 11,463 ) ( 12,963 ) Additional amounts deferred 8,275 18,790 Balance at end of period 27,622 30,810 Classified as: Current 13,486 13,490 Non-current 14,136 17,320 Total deferred contract costs (deferred commissions) $ 27,622 $ 30,810
Summary of Deferred Revenue Balances	A summary of the activity impacting deferred revenue balances during the nine months ended September 30, 2024 and for the year ended December 31, 2023 is presented below: (in thousands) Nine Months Ended September 30, 2024 Twelve Months Ended December 31, 2023 Balance at beginning of period $ 97,386 $ 99,928 Revenue recognized ( 189,914 ) ( 251,415 ) Additional amounts deferred 178,768 248,873 Balance at end of period $ 86,240 $ 97,386
Summary of Remaining Performance Obligation	The remaining performance obligations consisted of the following: (in thousands) September 30, December 31, Current $ 163,692 $ 187,331 Non-current 81,181 89,636 Total $ 244,873 $ 276,967

Short-Term Investments (Tables)

Short-Term Investments (Tables)	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Schedule of Short-term Investments	Short-term investments classified as available-for-sale consisted of the following: September 30, 2024 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term investments: US Treasuries $ 25,402 $ 9 $ — $ 25,411 Commercial paper 109,143 137 ( 3 ) 109,277 Certificates of deposit 33,055 36 — 33,091 Total short-term investments $ 167,600 $ 182 $ ( 3 ) $ 167,779 December 31, 2023 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term investments: US Treasuries $ 62,486 $ 20 $ ( 45 ) $ 62,461 Corporate Bonds 2,314 10 — 2,324 Commercial Paper 94,269 85 ( 18 ) 94,336 Certificates of Deposit 17,954 19 ( 2 ) 17,971 Total short-term investments $ 177,023 $ 134 $ ( 65 ) $ 177,092

Accounts Receivable, Net (Table

Accounts Receivable, Net (Tables)	9 Months Ended
	Sep. 30, 2024
Receivables [Abstract]
Schedule of Accounts Receivable,Net	Accounts receivable, net consisted of the following: (in thousands) September 30, December 31, Accounts receivable $ 37,640 $ 60,206 Unbilled receivable 499 1,346 38,139 61,552 Less: allowance for credit losses ( 2,385 ) ( 2,303 ) Accounts receivable, net $ 35,754 $ 59,249

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following: (in thousands) September 30, December 31, Computers and software $ 7,813 $ 6,921 Furniture and equipment 907 1,172 Leasehold improvements 1,832 2,338 Construction and software development in process 142 — 10,694 10,431 Less: accumulated depreciation and amortization ( 6,990 ) ( 5,960 ) Property and equipment, net $ 3,704 $ 4,471

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill	The carrying amounts of goodwill and intangible assets, as of September 30, 2024 and December 31, 2023, consisted of the following: September 30, 2024 (in thousands) Gross Accumulated Net Carrying Finite-lived intangible assets: Customer relationships $ 410,390 $ ( 188,358 ) $ 222,032 Developed technologies 85,191 ( 41,157 ) 44,034 Tradenames 36,121 ( 11,095 ) 25,026 Database 51,457 ( 48,019 ) 3,438 Total finite-lived intangible assets 583,159 ( 288,629 ) 294,530 Goodwill 490,343 — 490,343 Total goodwill and intangible assets $ 1,073,502 $ ( 288,629 ) $ 784,873 December 31, 2023 (in thousands) Gross Accumulated Net Carrying Finite-lived intangible assets: Customer relationships $ 410,210 $ ( 163,586 ) $ 246,624 Developed technologies 78,434 ( 33,769 ) 44,665 Tradenames 36,062 ( 9,379 ) 26,683 Database 50,221 ( 45,072 ) 5,149 Total finite-lived intangible assets 574,927 ( 251,806 ) 323,121 Goodwill 1,075,080 — 1,075,080 Total goodwill and intangible assets $ 1,650,007 $ ( 251,806 ) $ 1,398,201
Schedule of Future Amortization Expense	Estimated total intangible amortization expense during the next five years and thereafter is as follows: (in thousands) 2024, excluding the nine months ended September 30, 2024 $ 12,213 2025 47,425 2026 41,250 2027 35,045 2028 30,778 Thereafter 127,819 Total $ 294,530
Schedule of Goodwill	As of and for the periods ended September 30, 2024 and December 31, 2023, goodwill consisted of the following: (in thousands) Nine Months Ended Twelve Months Ended Goodwill, gross - beginning of period $ 1,362,480 $ 1,324,733 Accumulated impairment losses ( 287,400 ) — Goodwill, net - beginning of period 1,075,080 1,324,733 Goodwill acquired during period 7,057 37,747 Goodwill impairment loss ( 591,794 ) ( 287,400 ) Goodwill, net - end of period $ 490,343 $ 1,075,080 (in thousands) Nine Months Ended Twelve Months Ended Goodwill, gross - end of period $ 1,369,537 $ 1,362,480 Accumulated impairment losses ( 879,194 ) ( 287,400 ) Goodwill, net - end of period $ 490,343 $ 1,075,080

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	9 Months Ended
	Sep. 30, 2024
Accounts Payable and Accrued Liabilities, Current [Abstract]
Schedule of Accrued Expenses and Other Liabilities	Accrued expenses and other liabilities consisted of the following: (in thousands) September 30, December 31, Payroll and payroll-related $ 10,516 $ 12,805 Tax receivable agreement, current portion 13,075 20,095 Contingent consideration, current — 1,602 Sales, franchise, and other taxes 6,321 9,526 Other 5,839 7,501 Accrued expenses and other liabilities $ 35,751 $ 51,529
Schedule of Company's restructuring plan liabilities	The following table sets forth the activity in the Company’s liabilities resulting from the 2024 Restructuring Plan: (in thousands) Employee termination costs Balance at December 31, 2023 $ 122 Charges incurred 8,009 Cash payments made ( 7,677 ) Balance at September 30, 2024 $ 454

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2024
Long-Term Debt, Unclassified [Abstract]
Schedule of Long-term Debt	Long-term debt consisted of the following as of September 30, 2024 and December 31, 2023, respectively: September 30, 2024 (in thousands) Principal Unamortized debt Total debt, 2021 Term Loan $ 247,500 $ ( 1,082 ) $ 246,418 Less: current portion of long-term debt 13,750 Long-term debt $ 232,668 December 31, 2023 (in thousands) Principal Unamortized debt Total debt, 2021 Term Loan $ 257,813 $ ( 1,496 ) $ 256,317 Less: current portion of long-term debt 13,750 Long-term debt $ 242,567

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	9 Months Ended
	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Fair Values of the Interest Rate Swap	The fair values of the interest rate swaps and their respective locations in our unaudited condensed consolidated balance sheets at September 30, 2024 and December 31, 2023 were as follows: (in thousands) Description Balance Sheet Location September 30, 2024 December 31, 2023 Short-term derivative asset Prepaid expenses and other assets $ 1,426 $ 3,426 Long-term derivative asset Other assets — 509

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Schedule of Reconciliation of Earnout Liabilities Measured at Fair Value on a Recurring Basis Unobservable Inputs	The table below presents a reconciliation of earnout liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3): (in thousands) Nine Months Ended September 30, 2024 Twelve Months Ended December 31, 2023 Balance at beginning of period $ 10,352 $ 2,250 Additions — 7,800 Net change in fair value and other adjustments ( 3,240 ) 302 Payments ( 1,602 ) — Balance at end of period $ 5,510 $ 10,352
Schedule of Fair Value of Assets and Liabilities Measured at Fair Value on Recurring Basis	At September 30, 2024 and December 31, 2023, assets and liabilities measured at fair value on a recurring basis were as follows: September 30, 2024 (in thousands) Total Level 1 Level 2 Level 3 Assets: Cash and cash equivalents: Money market funds $ 107,711 $ 107,711 $ — $ — Short-term investments: U.S. Treasuries 25,411 — 25,411 — Commercial paper 109,277 — 109,277 — Certificates of deposit 33,091 — 33,091 — Prepaid expenses and other assets: Interest rate swap contracts 1,426 — 1,426 — Liabilities: Contingent consideration 5,510 — — 5,510 December 31, 2023 (in thousands) Total Level 1 Level 2 Level 3 Assets: Cash and cash equivalents: Money market funds $ 87,869 $ 87,869 $ — $ — Commercial paper (maturities less than 90 days) 4,227 — 4,227 — Certificates of deposit (maturities less than 90 days) 1,000 — 1,000 — Short-term investments: U.S. treasuries 62,461 — 62,461 — Corporate bonds 2,324 — 2,324 — Commercial paper 94,336 — 94,336 — Certificates of deposit 17,971 — 17,971 — Prepaid expenses and other assets: Interest rate swap contracts 3,426 — 3,426 — Other assets: Interest rate swap contracts 509 — 509 — Liabilities: Contingent consideration 10,352 — — 10,352

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2024
Stockholders' Equity Note [Abstract]
Summary of Changes in Accumulated Balances in Other Comprehensive Income	The following tables summarize the changes in accumulated balances of other comprehensive income for the three and nine months ended September 30, 2024 and 2023, respectively. Three Months Ended September 30, 2024 Nine Months Ended September 30, 2024 (in thousands) Unrealized Gain (Loss) on Cash Flow Hedges Unrealized (Loss) Gain on Investments Foreign Currency Translation Adjustments Total Unrealized Gain (Loss) on Cash Flow Hedges Unrealized Gain on Investments Foreign Currency Translation Adjustments Total Beginning balance $ 1,601 $ ( 50 ) $ ( 494 ) $ 1,057 $ 2,387 $ 96 $ ( 374 ) $ 2,109 Other comprehensive (loss) income before reclassifications ( 276 ) 219 159 102 599 73 39 711 Amounts reclassified from AOCI ( 815 ) — — ( 815 ) ( 2,476 ) — — ( 2,476 ) Ending balance $ 510 $ 169 $ ( 335 ) $ 344 $ 510 $ 169 $ ( 335 ) $ 344 Three months ended September 30, 2023 Nine months ended September 30, 2023 (in thousands) Unrealized Gain (Loss) on Cash Flow Hedges Unrealized (Loss) Gain on Investments Foreign Currency Translation Adjustments Total Unrealized Gain (Loss) on Cash Flow Hedges Unrealized Loss on Investments Foreign Currency Translation Adjustments Total Beginning balance $ 4,158 $ ( 326 ) $ ( 580 ) $ 3,252 $ 4,307 $ ( 135 ) $ ( 504 ) $ 3,668 Other comprehensive income (loss) before reclassifications 505 148 ( 22 ) 631 1,710 ( 43 ) ( 98 ) 1,569 Amounts reclassified from AOCI ( 832 ) — — ( 832 ) ( 2,186 ) — — ( 2,186 ) Ending balance $ 3,831 $ ( 178 ) $ ( 602 ) $ 3,051 $ 3,831 $ ( 178 ) $ ( 602 ) $ 3,051

Stockholders' Equity and Equi_2

Stockholders' Equity and Equity-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Equity Based Compensation Expense Recognized	A summary of the expense by line item in the unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023, respectively, is provided in the following table. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Cost of revenue $ 88 $ 276 $ 668 $ 830 Sales and marketing 829 2,728 4,786 8,297 Product development 1,218 3,236 6,928 9,566 General and administrative 4,161 5,754 18,338 16,792 Total compensation expense $ 6,296 $ 11,994 $ 30,720 $ 35,485

Loss Per Share (Tables)

Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share, Basic and Diluted	The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted net loss per share of Class A Common Stock for the three and nine months ended September 30, 2024 and 2023 . Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Numerator: Net loss $ ( 187,824 ) $ ( 248,688 ) $ ( 506,729 ) $ ( 276,265 ) Less: Net loss attributable to noncontrolling interests ( 56,928 ) ( 77,162 ) ( 152,680 ) ( 84,110 ) Net loss attributable to Definitive Healthcare Corp. $ ( 130,896 ) $ ( 171,526 ) $ ( 354,049 ) ( 192,155 ) The following table sets forth the computation of basic and diluted net loss per share of Class A Common Stock for the three and nine months ended September 30, 2024 and 2023 (per share amounts unaudited). Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except number of shares and per share amounts) 2024 2023 2024 2023 Basic net loss per share attributable to common stockholders Numerator: Allocation of net loss attributable to Definitive Healthcare Corp. $ ( 130,896 ) $ ( 171,526 ) $ ( 354,049 ) $ ( 192,155 ) Denominator: Weighted average number of shares of Class A Common Stock outstanding 116,382,021 114,527,514 117,185,701 111,533,166 Net loss per share, basic and diluted $ ( 1.12 ) $ ( 1.50 ) $ ( 3.02 ) $ ( 1.72 )
Schedule of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share	The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the period presented because their effect would have been anti-dilutive: Nine Months Ended September 30, 2024 2023 Definitive OpCo LLC Units (vested and unvested) 39,460,224 39,781,946 Restricted Stock Units 9,092,737 6,847,050

Organization and Basis of Pre_2

Organization and Basis of Presentation - Additional Information (Details)	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Entity Incorporation, Date of Incorporation	May 05, 2021

Acquisition - Additional Inform

Acquisition - Additional Information (Details) - USD ($) $ in Thousands			3 Months Ended	9 Months Ended
	Jan. 16, 2024	Jul. 21, 2023	Sep. 30, 2024	Sep. 30, 2024
Business Acquisition [Line Items]
Cash consideration paid at closing		$ 46,400
Purchase price		54,100
Working capital adjustment		100
Contingent consideration		28,000
Fair value of the contingent consideration		7,800
Software Development [Member]
Business Acquisition [Line Items]
Other assets		21,400
Developed Technology [Member]
Business Acquisition [Line Items]
Other assets	$ 6,800
Carevoyance
Business Acquisition [Line Items]
Purchase price	$ 13,700
Weighted average amortization period of finite-lived intangible assets acquired	6 years 10 months 24 days
Carevoyance | Developed Technology [Member]
Business Acquisition [Line Items]
Other assets	$ 6,800
Weighted average amortization period	7 years
Populi Inc.
Business Acquisition [Line Items]
Cash consideration paid at closing		4,800		$ 46,446
Purchase price				54,101
Working capital adjustment				(145)
Contingent consideration				7,800
Fair value of the contingent consideration		$ 7,800
Business combination, Acquisition related costs			$ 600	$ 1,700
Weighted average amortization period of finite-lived intangible assets acquired		7 years 2 months 12 days
Populi Inc. | Software Development [Member]
Business Acquisition [Line Items]
Other assets		$ 21,400
Weighted average amortization period		7 years
Trade Names [Member]
Business Acquisition [Line Items]
Other assets	$ 100	$ 100
Trademarks [Member] | Carevoyance
Business Acquisition [Line Items]
Other assets	$ 100
Weighted average amortization period	2 years
Trademarks [Member] | Populi Inc.
Business Acquisition [Line Items]
Other assets		$ 100
Weighted average amortization period		1 year
Customer Relationships [Member]
Business Acquisition [Line Items]
Other assets	$ 200	$ 800
Customer Relationships [Member] | Carevoyance
Business Acquisition [Line Items]
Other assets	$ 200
Weighted average amortization period	5 years
Customer Relationships [Member] | Populi Inc.
Business Acquisition [Line Items]
Other assets		$ 800
Weighted average amortization period		15 years
Goodwill [Member]
Business Acquisition [Line Items]
Other assets	$ 7,100	$ 37,700
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Potential payouts range, Low		0
Potential payouts range, High		$ 28,000

Acquisition - Summary of Transa

Acquisition - Summary of Transaction Transferred (Details) - USD ($) $ in Thousands		9 Months Ended
	Jul. 21, 2023	Sep. 30, 2024
Business Acquisition [Line Items]
Cash consideration paid at closing	$ 46,400
Working capital adjustment	100
Contingent consideration	28,000
Purchase price	54,100
Populi Inc.
Business Acquisition [Line Items]
Cash consideration paid at closing	$ 4,800	$ 46,446
Working capital adjustment		(145)
Contingent consideration		7,800
Purchase price		$ 54,101

Acquisitions - Summary of Alloc

Acquisitions - Summary of Allocation of Purchase Price to the Fair Value of Assets Acquired (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Mar. 31, 2024
Carevoyance
Accounts receivable	$ 605
Intangible assets	7,000
Deferred revenue	(987)
Total assets acquired and liabilities assumed	6,618
Goodwill	7,057
Purchase price	$ 13,675
Populi Inc.
Cash		$ 1,423
Accounts receivable		2,662
Prepaid expenses and other assets		153
Property and equipment		42
Intangible assets		22,330
Accounts payable and accrued expenses		(3,316)
Deferred revenue		(4,010)
Other liabilities		(2,930)
Total assets acquired and liabilities assumed		16,354
Goodwill		37,747
Purchase price		54,101
Populi Inc. | Preliminary, as originally reported
Cash		1,423
Accounts receivable		2,662
Prepaid expenses and other assets		153
Property and equipment		42
Intangible assets		22,830
Accounts payable and accrued expenses		(3,316)
Deferred revenue		(4,010)
Other liabilities		(2,354)
Total assets acquired and liabilities assumed		17,430
Goodwill		36,652
Purchase price		54,082
Populi Inc. | Measurement period adjustments
Cash		0
Accounts receivable		0
Prepaid expenses and other assets		0
Property and equipment		0
Intangible assets		(500)
Accounts payable and accrued expenses		0
Deferred revenue		0
Other liabilities		(576)
Total assets acquired and liabilities assumed		(1,076)
Goodwill		1,095
Purchase price		$ 19

Acquisitions - Schedule of Busi

Acquisitions - Schedule of Business Acquisition, Pro Forma Information (Details) - Populi, Inc. [Member] - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Business Acquisition [Line Items]
Revenue	$ 66,225	$ 189,697
Net loss	$ (248,940)	$ (280,870)

Revenue - Schedule of Disaggreg

Revenue - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation Of Revenue [Line Items]
Revenue	$ 62,697	$ 65,325	$ 189,914	$ 185,483
Subscription Services [Member]
Disaggregation Of Revenue [Line Items]
Revenue	60,897	62,568	184,645	180,358
Professional Services [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 1,800	$ 2,757	$ 5,269	$ 5,125

Revenue - Summary of Deferred C

Revenue - Summary of Deferred Contract Costs (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Additional amounts deferred	$ 178,768		$ 248,873
Current	14,136		17,320
Total deferred contract costs (deferred commissions)	(8,275)	$ (13,020)
Deferred Contract Costs [Member]
Disaggregation of Revenue [Line Items]
Balance at beginning of period	30,810	$ 24,983	24,983
Costs amortized	(11,463)		(12,963)
Additional amounts deferred	8,275		18,790
Balance at end of period	27,622		30,810
Current	13,486		13,490
Non-current	14,136		17,320
Total deferred contract costs (deferred commissions)	$ 27,622		$ 30,810

Revenue - Summary of Deferred R

Revenue - Summary of Deferred Revenue Balances (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Balance at beginning of period	$ 97,386	$ 99,928
Revenue recognized	(189,914)	(251,415)
Additional amounts deferred	178,768	248,873
Balance at end of period	$ 86,240	$ 97,386

Revenue - Summary of Remaining

Revenue - Summary of Remaining Performance Obligation (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Current	$ 163,692	$ 187,331
Non-current	81,181	89,636
Total	$ 244,873	$ 276,967

Short-Term Investments - Schedu

Short-Term Investments - Schedule of Short-term Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	$ 167,600	$ 177,023
Gross unrealized gains	182	134
Gross unrealized losses	(3)	(65)
Fair Value	167,779	177,092
U.S. Treasuries [Member]
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	25,402	62,486
Gross unrealized gains	9	20
Gross unrealized losses	0	(45)
Fair Value	25,411	62,461
Corporate Bonds [Member]
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost		2,314
Gross unrealized gains		10
Gross unrealized losses		0
Fair Value		2,324
Commercial Paper [Member]
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	109,143	94,269
Gross unrealized gains	137	85
Gross unrealized losses	(3)	(18)
Fair Value	109,277	94,336
Certificates of Deposit [Member]
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	33,055	17,954
Gross unrealized gains	36	19
Gross unrealized losses	0	(2)
Fair Value	$ 33,091	$ 17,971

Short-Term Investments - Additi

Short-Term Investments - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Amount of net accumulated accretion included in amortized cost	$ 1.8		$ 1.8		$ 2.8
Interest accretion on short-term investments	$ 1.6	$ 2.1	$ 5.4	$ 5.8

Accounts Receivable, Net - Sche

Accounts Receivable, Net - Schedule of Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Receivables [Abstract]
Accounts receivable	$ 37,640	$ 60,206
Unbilled receivable	499	1,346
Accounts Receivable, before Allowance for Credit Loss, Current	38,139	61,552
Less: allowance for credit losses	(2,385)	(2,303)
Accounts receivable, net	$ 35,754	$ 59,249

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 10,694	$ 10,431
Less: accumulated depreciation and amortization	(6,990)	(5,960)
Property and equipment, net	3,704	4,471
Computers and Software [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	7,813	6,921
Furniture and Equipment [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	907	1,172
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	1,832	2,338
Construction and Software Development in Process [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 142	$ 0

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Property Plant And Equipment [Line Items]
Depreciation and amortization	$ 9,474		$ 9,795	$ 28,205	$ 29,073
Impairment charges		$ 1,000
Operating lease impairment loss		700		1,047	155
Impairment charges on leasehold improvements		300
Property, plant and equipment, disposals		1,000
Furniture and Equipment [Member]
Property Plant And Equipment [Line Items]
Accelerated depreciation		$ 100
Property Plant And Equipment [Member]
Property Plant And Equipment [Line Items]
Depreciation and amortization	$ 500		$ 400	$ 1,700	$ 1,300

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Intangible Assets and Goodwill (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 583,159	$ 574,927
Accumulated Amortization	(288,629)	(251,806)
Net Carrying Amount	294,530	323,121
Goodwill [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	490,343	1,075,080
Accumulated Amortization	0	0
Net Carrying Amount	490,343	1,075,080
Goodwill And Intangible Assets [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,073,502	1,650,007
Accumulated Amortization	(288,629)	(251,806)
Net Carrying Amount	784,873	1,398,201
Customer Relationships [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	410,390	410,210
Accumulated Amortization	(188,358)	(163,586)
Net Carrying Amount	222,032	246,624
Developed Technologies [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	85,191	78,434
Accumulated Amortization	(41,157)	(33,769)
Net Carrying Amount	44,034	44,665
Trade Names [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	36,121	36,062
Accumulated Amortization	(11,095)	(9,379)
Net Carrying Amount	25,026	26,683
Database [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	51,457	50,221
Accumulated Amortization	(48,019)	(45,072)
Net Carrying Amount	$ 3,438	$ 5,149

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Additional Information (Details) $ in Thousands	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) Segment	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets				$ 36,816	$ 37,358
Amortization	$ 3,589		$ 3,232	$ 10,330	9,676
Number of Reporting Units | Segment				1
Goodwill impairment	228,153	$ 363,600	287,400	$ 591,794	287,400	$ 287,400
Finite Lived Intangible Assets [Member]
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets	12,500		12,600	36,800	37,400
Amortization	$ 3,600		$ 3,200	$ 10,300	$ 9,700

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Future Amortization Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
2024, excluding the nine months ended September 30, 2024	$ 12,213
2025	47,425
2026	41,250
2027	35,045
2028	30,778
Thereafter	127,819
Net Carrying Amount	$ 294,530	$ 323,121

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, gross - beginning of period				$ 1,362,480	$ 1,324,733	$ 1,324,733
Accumulated impairment losses	$ (879,194)			(879,194)		(287,400)
Goodwill, gross - end of period	1,369,537			1,369,537		1,362,480
Goodwill, net - beginning of period				1,075,080	1,324,733	1,324,733
Goodwill acquired during period				7,057		37,747
Goodwill impairment loss	(228,153)	$ (363,600)	$ (287,400)	(591,794)	$ (287,400)	(287,400)
Goodwill, net - end of period	$ 490,343			$ 490,343		$ 1,075,080

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses And Other Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Accounts Payable and Accrued Liabilities, Current [Abstract]
Payroll and payroll-related	$ 10,516	$ 12,805
Tax receivable agreement, current portion	13,075	20,095
Contingent consideration, current	0	1,602
Sales, franchise and other taxes	6,321	9,526
Other	5,839	7,501
Accrued expenses and other liabilities	$ 35,751	$ 51,529

Accrued Expenses and Other Li_4

Accrued Expenses and Other Liabilities - Additional Information (Details) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($) Workforce
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges	$ 0.2	$ 8
Restructuring and related cost, remaining	$ 0.5	$ 0.5
Reduction of current workforce | Workforce		150

Accrued Expenses and Other Li_5

Accrued Expenses and Other Liabilities - Schedule of Company's Restructuring Plan Liabilities (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Restructuring Reserve [Abstract]
Beginning Balance	$ 122
Charges incurred	8,009
Cash payments made	(7,677)
Ending Balance	$ 454

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Less: current portion of long-term debt	$ 13,750	$ 13,750
Long-term debt	232,668	242,567
2021 Term Loan [Member]
Debt Instrument [Line Items]
Principal	247,500	257,813
Unamortized debt issuance costs / financing costs	(1,082)	(1,496)
Total debt, net	$ 246,418	$ 256,317

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Frequency of payment		The 2021 Term Loan is subject to annual amortization of principal, payable in equal quarterly installments on the last day of each fiscal quarter, commencing on December 31, 2021 (the “Initial Amortization Date”), equal to approximately 2.5% per annum of the principal amount of the term loans in the first year and second year after the Initial Amortization Date and approximately 5.0% per annum of the principal amount of the term loans in the third year, fourth year, and fifth year after the Initial Amortization Date.
Financing costs		$ 3,500
Standby Letters of Credit [Member]
Debt Instrument [Line Items]
Letters of Credit Outstanding, Amount			$ 600
2021 Term Loan [Member]
Debt Instrument [Line Items]
Repayment of debt		10,300
Outstanding principal balance		247,500	257,813
Line of credit	$ 275,000
Balloon payment		220,000
Financing costs		2,800
Unamortized debt issuance costs / financing costs		(1,082)	(1,496)
2021 Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Maturity date	Sep. 17, 2026
Line of credit	$ 75,000	$ 74,400
Interest rate		6.70%
Financing costs		$ 800
Unamortized debt issuance costs / financing costs		$ (300)	$ (400)
2021 Revolving Line of Credit [Member] | Minimum [Member]
Debt Instrument [Line Items]
Unused commitment fee percentage		0.25%
2021 Revolving Line of Credit [Member] | Maximum [Member]
Debt Instrument [Line Items]
Unused commitment fee percentage		0.30%

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Additional Information (Details) - Interest Rate Swaps [Member] $ in Millions	9 Months Ended
	Sep. 30, 2024 USD ($) Segment	Mar. 31, 2022 Segment
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Number of Instruments Held | Segment	2	2
Notional amount	$ 61.9
Maturity date	Mar. 31, 2025
Net pre-tax gains	$ 1.4
Goldman Sachs Bank USA [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Fixed interest rates	1.9065%
Bank of America N.A [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Fixed interest rates	1.909%

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Summary of Fair Values of the Interest Rate Swap (Details) - Interest Rate Swap [Member] - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Short-term derivative asset	$ 1,426	$ 3,426
Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration]	Prepaid Expense and Other Assets, Current	Prepaid Expense and Other Assets, Current
Long-term derivative asset	$ 0	$ 509
Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Assets, Noncurrent	Other Assets, Noncurrent

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) $ in Millions	Sep. 30, 2024 USD ($)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Business combination, contingent consideration, liability	$ 5.5

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Reconciliation of Earnout Liabilities Measured at Fair Value on a Recurring Basis Unobservable Inputs (Details) - Fair Value, Inputs, Level 3 - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Balance at beginning of period	$ 10,352	$ 2,250
Additions	0	7,800
Net change in fair value and other adjustments	(3,240)	302
Payments	(1,602)	0
Balance at end of period	$ 5,510	$ 10,352

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Fair Value of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ 0	$ (7,800)
Recurring [Member] | U.S. Treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	25,411		$ 62,461
Recurring [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			2,324
Recurring [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	109,277		94,336
Recurring [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	33,091		17,971
Recurring [Member] | Interest Rate Swap [Member] | Prepaid Expenses and Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	1,426		3,426
Recurring [Member] | Interest Rate Swap [Member] | Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			509
Recurring [Member] | Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	5,510		10,352
Recurring [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	107,711		87,869
Recurring [Member] | Commercial Paper Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			4,227
Recurring [Member] | Certificates of Deposit Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			1,000
Level 1 [Member] | Recurring [Member] | U.S. Treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 1 [Member] | Recurring [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			0
Level 1 [Member] | Recurring [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 1 [Member] | Recurring [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 1 [Member] | Recurring [Member] | Interest Rate Swap [Member] | Prepaid Expenses and Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 1 [Member] | Recurring [Member] | Interest Rate Swap [Member] | Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			0
Level 1 [Member] | Recurring [Member] | Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0		0
Level 1 [Member] | Recurring [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	107,711		87,869
Level 1 [Member] | Recurring [Member] | Commercial Paper Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			0
Level 1 [Member] | Recurring [Member] | Certificates of Deposit Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			0
Level 2 [Member] | Recurring [Member] | U.S. Treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	25,411		62,461
Level 2 [Member] | Recurring [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			2,324
Level 2 [Member] | Recurring [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	109,277		94,336
Level 2 [Member] | Recurring [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	33,091		17,971
Level 2 [Member] | Recurring [Member] | Interest Rate Swap [Member] | Prepaid Expenses and Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	1,426		3,426
Level 2 [Member] | Recurring [Member] | Interest Rate Swap [Member] | Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			509
Level 2 [Member] | Recurring [Member] | Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0		0
Level 2 [Member] | Recurring [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 2 [Member] | Recurring [Member] | Commercial Paper Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			4,227
Level 2 [Member] | Recurring [Member] | Certificates of Deposit Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			1,000
Level 3 [Member] | Recurring [Member] | U.S. Treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 3 [Member] | Recurring [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			0
Level 3 [Member] | Recurring [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 3 [Member] | Recurring [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 3 [Member] | Recurring [Member] | Interest Rate Swap [Member] | Prepaid Expenses and Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 3 [Member] | Recurring [Member] | Interest Rate Swap [Member] | Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			0
Level 3 [Member] | Recurring [Member] | Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	5,510		10,352
Level 3 [Member] | Recurring [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	$ 0		0
Level 3 [Member] | Recurring [Member] | Commercial Paper Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			0
Level 3 [Member] | Recurring [Member] | Certificates of Deposit Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			$ 0

Stockholders' Equity and Member

Stockholders' Equity and Members' Equity - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023
Class Of Stock [Line Items]
Equity-based compensation	$ 6,296	$ 8,842	$ 15,582	$ 11,994	$ 12,363	$ 11,128

Noncontrolling Interest - Addit

Noncontrolling Interest - Additional Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Noncontrolling Interest [Line Items]
Tax withholding obligation	$ 7,270	$ 3,397
Common Class A
Noncontrolling Interest [Line Items]
Common stock, shares outstanding	115,443,795		116,562,252
Repurchased Shares	3,144,516
Definitive OpCo [Member]
Noncontrolling Interest [Line Items]
Ownership interest (as a percent)	74.60%		74.90%
Noncontrolling interest	25.40%		25.10%
Definitive OpCo [Member] | Common Class A
Noncontrolling Interest [Line Items]
Common stock, shares outstanding	249,225
Tax withholding obligation	$ 918,054
Antidilutive securities excluded from computation of earnings per share, amount	2,694,888
Issuance of common stock shares	1,776,834

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income - Summary of Changes in Accumulated Balances in Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Unrealized Gain (Loss) on Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	$ 1,601	$ 4,158	$ 2,387	$ 4,307
Other comprehensive (loss) income before reclassifications	(276)	505	599	1,710
Amounts reclassified from AOCI	(815)	(832)	(2,476)	(2,186)
Ending Balance	510	3,831	510	3,831
Unrealized (Loss) Gain on Investments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(50)	(326)	96	(135)
Other comprehensive (loss) income before reclassifications	219	148	73	(43)
Amounts reclassified from AOCI	0	0	0	0
Ending Balance	169	(178)	169	(178)
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(494)	(580)	(374)	(504)
Other comprehensive (loss) income before reclassifications	159	(22)	39	(98)
Amounts reclassified from AOCI	0	0	0	0
Ending Balance	(335)	(602)	(335)	(602)
AOCI Attributable to Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	1,057	3,252	2,109	3,668
Other comprehensive (loss) income before reclassifications	102	631	711	1,569
Amounts reclassified from AOCI	(815)	(832)	(2,476)	(2,186)
Ending Balance	$ 344	$ 3,051	$ 344	$ 3,051

Stockholders' Equity and Equi_3

Stockholders' Equity and Equity-Based Compensation - Summary of Equity Based Compensation Expense Recognized (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 6,296	$ 11,994	$ 30,720	$ 35,485
Cost of Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	88	276	668	830
Sales and Marketing
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	829	2,728	4,786	8,297
Product Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,218	3,236	6,928	9,566
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 4,161	$ 5,754	$ 18,338	$ 16,792

Stockholders' Equity and Equi_4

Stockholders' Equity and Equity-Based Compensation - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	May 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Payment Arrangement, Expense	$ 6,296	$ 11,994	$ 30,720	$ 35,485
Common Class A
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Amount of repurchased shares	$ 15,000		$ 15,000		$ 20,000
Repurchased Shares	3,144,516		3,144,516
Share Repurchase Program, Authorized, Amount	$ 15,000		$ 15,000		$ 20,000
Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Payment Arrangement, Expense	$ 100		$ 7,400
Employee [Member] | Time-based RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation accelerated vesting number of shares	28,879		779,024
Employee [Member] | Performance-Based RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation accelerated vesting number of shares	9,300		58,565
Employee [Member] | Definitive OpCo
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation accelerated vesting number of shares	7,839		67,937

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Effective tax rate	6.80%	6.60%	6.70%	6.70%
Deferred tax liabilities	$ 30.6		$ 30.6		$ 67.2
Tax receivable agreement liability			$ 72.1		$ 147.1
Tax receivable agreement realized tax benefits payable to related parties percent			85%
Tax Receivable Agreement Benefit percentage			15%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21%
TRA Remeasurement Gain (Loss)	$ 24.2	$ 29.7	$ 68.2	$ 25

Loss Per Share - Schedule of Ne

Loss Per Share - Schedule of Net Loss Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Net loss	$ (187,824)	$ (306,187)	$ (12,718)	$ (248,688)	$ (11,605)	$ (15,972)	$ (506,729)	$ (276,265)
Less: Net loss attributable to noncontrolling interests	(56,928)			(77,162)			(152,680)	(84,110)
Net loss attributable to Definitive Healthcare Corp.	(130,896)			(171,526)			(354,049)	(192,155)
Basic net loss per share attributable to common stockholders [Abstract]
Allocation of net loss attributable to Definitive Healthcare Corp.	$ (130,896)			$ (171,526)			$ (354,049)	$ (192,155)
Weighted average number of shares of Class A outstanding	116,382,021			114,527,514			117,185,701	111,533,166
Net loss per share, basic	$ (1.12)			$ (1.5)			$ (3.02)	$ (1.72)
Net loss per share, diluted	$ (1.12)			$ (1.5)			$ (3.02)	$ (1.72)
Common Class A [Member]
Net loss	$ (187,824)			$ (248,688)			$ (506,729)	$ (276,265)
Less: Net loss attributable to noncontrolling interests	(56,928)			(77,162)			(152,680)	(84,110)
Net loss attributable to Definitive Healthcare Corp.	(130,896)			(171,526)			(354,049)	(192,155)
Basic net loss per share attributable to common stockholders [Abstract]
Allocation of net loss attributable to Definitive Healthcare Corp.	$ (130,896)			$ (171,526)			$ (354,049)	$ (192,155)
Weighted average number of shares of Class A outstanding	116,382,021			114,527,514			117,185,701	111,533,166
Net loss per share, basic	$ (1.12)			$ (1.5)			$ (3.02)	$ (1.72)
Net loss per share, diluted	$ (1.12)			$ (1.5)			$ (3.02)	$ (1.72)

Loss Per Share - Schedule of Di

Loss Per Share - Schedule of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Vested and Unvested Units [Member]
Antidilutive securities excluded from computation of earnings per share, amount	39,460,224	39,781,946
Restricted Stock Unit [Member]
Antidilutive securities excluded from computation of earnings per share, amount	9,092,737	6,847,050

Related parties - Additional In

Related parties - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
Revenue	$ 62,697	$ 65,325	$ 189,914	$ 185,483
Accounts receivable, net	35,754		35,754		$ 59,249
Related Party [Member]
Related Party Transaction [Line Items]
Revenue	300	$ 300	700	$ 1,100
Accounts receivable, net	$ 100		$ 100		$ 900

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($)	Nov. 30, 2024	Nov. 07, 2024	Nov. 01, 2024	Sep. 30, 2024	May 31, 2024
Forecast | Advent
Subsequent Event [Line Items]
Percentage of outstanding voting securities	40.30%
Common Class A
Subsequent Event [Line Items]
Amount of repurchased shares				$ 15,000,000	$ 20,000,000
Common Class A | Subsequent Event
Subsequent Event [Line Items]
Amount of repurchased shares		$ 0	$ 100,000,000